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ABSTRACT OF THE DISSERTATION
Regulation of Epithelial Turnover by Host-Virome Interactions
by
Lulu Sun
Doctor of Philosophy in Biology and Biomedical Sciences
Immunology
Washington University in St. Louis, 2016
Professor Thaddeus S. Stappenbeck, Chair
The host immune system must constantly function to maintain chronic commensal and
pathogenic organisms in check. These organisms include the virome, which is the viral
component of the microbiome. The consequences of immune responses to the virome on host
physiology are as yet unexplored, and may have long-term implications in health and disease.
Here, I used both genetic and infectious mouse models to investigate how the innate antiviral
cytokines Type I interferons (IFNs) modulate epithelial turnover. I first found that mice deficient
in Irgm1, a p47 GTPase, had persistently elevated Type I IFNs even in the absence of exogenous
viral infection. The Irgm1-/- mouse enabled us to study the effects of Type I IFNs on host
physiology without the compounding variables imposed by a complex viral infection. I found
that Type I IFNs increased epithelial turnover in multiple organs. Chronic viral infection, which
induces Type I IFN production, also augmented epithelial turnover, demonstrating the
physiological relevance of this process. I discovered that Type I IFNs acted through nonepithelial cells, including macrophages, to promote increased epithelial turnover and wound
repair. Downstream of Type I IFN signaling, the highly related IFN-stimulated genes
Apolipoprotein L9a and b stimulated epithelial proliferation through ERK activation. These
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findings demonstrate that the host immune response to chronic viral infection has systemic
effects on epithelial turnover through a myeloid-epithelial circuit. This work advances our
understanding of the mechanisms that modulate proliferation and cell death of epithelial barriers
that provide the first line of protection against the environment.
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CHAPTER ONE:
Introduction: Epithelial Turnover, Type I Interferons, and Host-Virome Interactions
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Proliferation and Turnover of Epithelial Barriers
Epithelial cells make up linings and ducts within many organs in the body, including the
digestive and reproductive systems, endocrine and exocrine organs, and also form the surface
epidermis (Blanpain et al., 2007). They are continuous sheets of cells joined together by tight
junctions, adherens junctions, and desmosomes. The presence of these intercellular junctions
maintains epithelial cell polarity, allowing separation of apical and basolateral surfaces (Shin et
al., 2006). Epithelial cells can form a single layer (simple epithelium) or multiple layers
(stratified epithelium) on top of a basement membrane separating them from surrounding stromal
cells and mesenchyme. This highly organized structure is important for the many complex
functions that epithelial cells perform, such as glandular secretion, absorption, and transcellular
transport.
The epithelium is also the host's first line of defense against the environment. A central
part of this protection involves cell turnover, a regulated shedding and regeneration of
differentiated tissue cells while maintaining barrier integrity. Different epithelial surfaces and
organs have varying rates of turnover at homeostasis, but what regulates these rates is not well
understood. For example, the small intestine has a turnover rate of once every 5 days, while the
lung epithelium turns over up to once every 6 months (Blanpain et al., 2007). Organs with high
intrinsic rates of turnover include the intestine, epidermis, lung, thymus, testis, uterus, and
mammary gland (Pellettieri and Sanchez Alvarado, 2007). Other organs may have slower basal
rates of epithelial turnover, such as the pancreas, kidney, liver, and cornea (Pellettieri and
Sanchez Alvarado, 2007). Amazingly, it has been estimated that we produce and eliminate a
mass of cells equal to our body weight in a year (Reed, 1999).
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There are three aspects to cellular turnover of adult tissue: generation of new cells,
differentiation of newly-generated cells, and cell death. New cells are thought to be generated
from adult stem cells that are present in most, if not all, adult organs (Raff, 2003). Stem cells, by
definition, are able to self-renew and differentiate into cell lineages from their tissue of origin
(Blanpain et al., 2007). In certain organs, such as liver and pancreas, new cells may also
originate from division of differentiated cells (Dor et al., 2004; Taub, 2004). Newly generated
cells usually undergo a transitional phase of proliferation, known as the transit-amplifying phase,
before differentiation (Raff, 2003). It is thought that differentiation involves movement of the
precursor cell away from the stem cell niche, where it then receives different extrinsic and
perhaps also intrinsic cues for differentiation (Pellettieri and Sanchez Alvarado, 2007). Finally,
during homeostatic turnover, differentiated cells undergo cell death, maintaining organ
morphology and size. Apoptosis, rather than necrosis, is believed to be the main form of cell
death during homeostasis (Pellettieri and Sanchez Alvarado, 2007). During apoptosis, cells
undergo programmed cell death in which DNA is degraded and cellular contents are packaged
into apoptotic bodies that are phagocytosed by nearby phagocytes. This is in contrast to necrosis,
in which cells rupture, releasing their contents and inducing inflammation (Edinger and
Thompson, 2004).
A balance between the counteracting processes of cell generation and cell death is
necessary to maintain homeostatic turnover. Excessive cell death without regeneration can result
in degenerative disorders and could play a role in aging (Sharpless and DePinho, 2004). On the
other hand, uncontrolled proliferation without appropriate apoptosis can result in cancerous
growth (Green and Evan, 2002). The relationship between cell generation and cell death during
turnover is not well understood. It is not known whether dying cells promote proliferation of
3	
  
	
  

nearby cells, or whether proliferating cells promote apoptosis in neighbouring cells.
Understanding the mechanisms by which cell generation and cell death are linked and regulated
will provide valuable insights into disease pathogenesis.
Epithelial turnover has perhaps been best studied in the intestine, where the three features
of epithelial turnover (generation, differentiation, and death) take place in discrete compartments
(Figure 1.1). The intestinal mucosa consists of a simple epithelial layer forming crypts and, in
the small intestine, villus units (Radtke and Clevers, 2005). Four types of differentiated epithelial
cells exist: i) Paneth cells, which secrete anti-microbial peptides; ii) enterocytes, which form the
majority of intestinal epithelial cells and absorb nutrients; iii) goblet cells, which secrete mucus;
and iv) enteroendocrine cells, which secrete peptide hormones. Stem cells are located at the base
of intestinal crypts, between Paneth cells, and rapidly divide to produce precursor cells (Blanpain
et al., 2007). These cells move upward into the transit amplifying compartment and undergo
proliferation. Cells then differentiate as they migrate up the crypt, and in the small intestine, up
the villi. Paneth cells are an exception, as they migrate downward to the base of the crypt.
Differentiated cells undergo apoptosis at the tips of the villi in the small intestine or at the top of
the crypt in the large intestine and are shed into the lumen (Figure 1.1) (Creamer, 1967).
The rate of intestinal epithelial turnover is quite high, with regeneration occurring
approximately once every 5 days, and can be modulated by different environmental conditions
(Blanpain et al., 2007). For example, starvation, malnutrition, irradiation, and drugs have been
observed to alter this intrinsic rate (Creamer, 1967). Intestinal epithelial turnover has also been
shown to increase during bacterial infection with Citrobacter rodentium, a murine model of
infectious colitis (Bhinder et al., 2013; Luperchio and Schauer, 2001). In addition, Cliffe et al
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proposed that increased epithelial turnover acts as an "epithelial escalator" to expel Trichuris
muris, a murine parasite, from the intestine (Cliffe et al., 2005).
The turnover rate can also be modulated in response to injury, which may be important
for proper healing. For example, after physical injury in a wound biopsy system where whole
colonic crypts are excised using forceps, crypts adjacent to the wound proliferate to regenerate
the intestinal architecture (Seno et al., 2009). In this model, decreased epithelial proliferation was
associated with impaired wound healing, demonstrating the importance of this process in repair.
In many of these intestinal models, immune cytokines and signaling pathways have been
shown to play an important role in accelerating epithelial turnover. In the wound biopsy system,
delayed wound repair was observed in WT mice given neutralizing antibodies against IL-4 and
IL-13, and in mice deficient in Stat6 (a downstream mediator of IL-4 and IL-13 signaling) (Seno
et al., 2009). Myeloid differentiation factor 88 (Myd88), an adaptor protein downstream of Tolllike receptors, is necessary for epithelial hyperproliferation in response to Citrobacter infection
in mice (Gibson et al., 2008). The loss of epithelial hyperproliferation and repair in this model
resulted in loss of epithelial barrier integrity and bacterial invasion of the crypts (Gibson et al.,
2008). MyD88-/- mice also showed deficiencies in epithelial proliferation and wound repair in
response to dextran sodium sulfate, a chemical that induces an inflammatory colitis (Brown et
al., 2007). Finally, in Trichuris muris infection, epithelial proliferation was increased by IL-13
signaling and diminished by the chemokine CXCL10 (Cliffe et al., 2005). These findings all
support a role for the immune system in modulating epithelial turnover responses to injury and
infection.
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Host-Virome Interaction
Notably, the role of viruses in the regulation of epithelial turnover is unknown. Since all
individuals possess a collection of chronic viruses (a virome) as part of their metagenome, the
effects of these microbes on the host should be considered. Research into the virome has lagged
behind studies of the bacterial component of the microbiome, as new bioinformatic and
sequencing technology has only recently enabled detailed study of commensal and chronic
viruses. In a recent review, H.W. Virgin compartmentalized the virome into four components:
viruses that infect eukaryotic cells, viruses that infect bacteria (bacteriophages), viruses that
infect archaea, and virus-derived genetic elements in the host chromosomes (e.g. endogenous
retroviruses) (Virgin, 2014). In contrast to bacteria, which in a healthy individual are generally
isolated to mucosal surfaces, viruses can be harbored systemically. It is estimated that a healthy
individual possesses at least ten chronic systemic viruses at any given time, including
herpesviruses, anelloviruses, adenoviruses, papillomaviruses, and polyomaviruses, among others.
(Virgin, 2014; Virgin et al., 2009). Hepatitis B, hepatitis C and HIV are also prevalent in the
general population.
Some of these viruses may have little effect on host physiology, while other viruses
continuously stimulate the host immune system with increasingly appreciated consequences
(Virgin, 2014; Virgin et al., 2009). Stimulation of the immune response can occur during initial
infection, continuous replication, or reactivation from latent states. The anti-viral immune
response is necessary to keep many of these chronic infections in check. In acquired
immunodeficiency, where active surveillance by the immune response is diminished or absent,
normally quiescent viruses such as Epstein Barr virus (also known as human herpesvirus 4
(HHV4)), Kaposi's sarcoma virus (HHV8), and human polyomavirus JC virus can reactivate and
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cause disease (Bellizzi et al., 2013; Cesarman, 2014). In addition, components of the anti-viral
immune response have been linked to complex diseases such as Type I diabetes, inflammatory
bowel disease, and asthma, suggesting a role for viral infection in disease pathogenesis (Foxman
and Iwasaki, 2011). Viral infection alone is likely not sufficient to induce disease; host genetic
predisposition also plays an integral role. For example, persistent murine norovirus infection
promoted Paneth cell dysfunction and abnormal response to intestinal injury, but only in
genetically susceptible animals (Cadwell et al., 2010). Given the pervasiveness of viral infection
and the association of viruses with complex human diseases, the consequences of long-term
activation of the antiviral immune system on the host should be explored.

The Type I Interferon Signaling System
The central axis of anti-viral defense is the Type I IFN system. Type I IFNs are a family
of innate immune cytokines that are produced in response to viral and other types of infection
(Durbin et al., 2000; Muller et al., 1994) . They include multiple IFNαs, IFNβ, and other
subtypes, including IFNκ, IFNω, IFNζ, IFNε and two that exist only in pigs and cattle, IFNδ and
IFNτ (Hardy et al., 2004; Pestka et al., 2004). The Type I IFN gene locus is located in a cluster
on chromosome 9p in humans and on chromosome 4 in mice (Pestka et al., 2004). They are
conserved across all vertebrate species, and are an important link between the innate immune and
adaptive immune systems (Stetson and Medzhitov, 2006).
Type I IFNs can be induced by three types of recognition sensors that detect viral nucleic
acids within their respective compartments: Toll-like receptors (TLRs) that bind foreign nucleic
acid in extracellular and endosomic spaces, RIG-I-like receptors (RLRs) that recognize cytosolic
RNA, and sensors of cytosolic DNA (Figure 1.2). The TLRs are primarily expressed on
7	
  
	
  

macrophages and dendritic cells (DCs), central sentinel cells of the immune system. In particular,
plasmacytoid dendritic cells are thought to be the primary producers of high levels of Type I
IFNs during infection (Colonna et al., 2004). TLR3 recognizes double-stranded (ds) RNA, found
in both DNA and RNA viruses (Alexopoulou et al., 2001). TLR7 and TLR8 bind to singlestranded (ss) RNA, while TLR9 detects unmethylated CpG sequences that are uncommon in
vertebrate genomes but are found in the genomes of DNA viruses and bacteria (Diebold et al.,
2004; Heil et al., 2004; Hemmi et al., 2000). TLR4 is also able to stimulate Type I IFN
production downstream of lipopolysaccharide (LPS) recognition, through the adaptor protein
TIR-domain-containing adapter-inducing IFNβ (TRIF) (Yamamoto et al., 2002). TLRs 3, 7 and 9
are localized within the endosomal compartment, while TLR4 is expressed on the plasma
membrane surface. This localization allows TLRs to detect viral material originating outside the
cell.
In contrast, RLRs are RNA helicases expressed in the cytosol, enabling detection of
intracellular viral nucleic acid. The two RLRs, retinoic acid-inducible gene 1 (RIG-I) and
melanoma differentiation-associated protein 5 (MDA-5) both detect dsRNA. RIG-I is thought to
recognize shorter RNA strands with 5' triphosphate ends, or RNA that assumes complex
secondary structures, while MDA-5 recognizes longer RNA molecules (Loo et al., 2008). Both
interact with the adaptor molecule interferon-beta promoter stimulator 1 (IPS-1), also known as
mitochondrial antiviral-signaling protein (MAVS), found in the outer mitochondrial membrane
(Kawai et al., 2005; Seth et al., 2005).
Multiple candidate factors for sensing foreign cytosolic DNA have been proposed, but
most are thought to signal through the adaptor protein stimulator of interferon genes (STING)
found on the endoplasmic reticulum membrane (Ishikawa and Barber, 2008). Most recently,
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cyclic GMP-AMP (cGAMP) synthase (cGAS) has been suggested as a cytosolic DNA sensor
(Sun et al., 2013; Wu et al., 2013). Upon binding of foreign DNA, it synthesizes cGAMP from
ATP and GTP, which then activate STING (Sun et al., 2013; Wu et al., 2013). Previously
proposed candidates include RNA polymerase III, which can transcribe AT-rich DNA (found in
some pathogen genomes) into dsRNA that can be recognized by RIG-I (Ablasser et al., 2009;
Chiu et al., 2009), and DExD/H box helicases (Kim et al., 2010; Zhang et al., 2011). The pyrin
and HIN domain-containing family (PYHIN) protein IFI16 has also been shown to bind dsDNA
and trigger STING activation (Unterholzner et al., 2010). It is unclear whether these proposed
sensors have distinct roles in particular cell types or whether they act concurrently to recognize
foreign DNA and induce Type I IFN production.
Downstream of i) TLR, ii) RLR and iii) STING signaling is the activation of transcription
factors called interferon regulatory factors (IRFs) (Figure 1.2). Four IRFs can positively regulate
Type I IFN production: IRF1, 3, 5 and 7, but only IRF3 and IRF7 have been shown to be key
inducers of Type I IFN gene expression in response to viruses (Honda et al., 2006). IRF3 is
constitutively expressed, while IRF7 is normally present at low amounts and strongly induced by
Type I IFN signaling itself (Marie et al., 1998). Once IRF3 and IRF7 are activated, they
dimerize, move to the nucleus and form a complex with coactivators to drive transcription of the
Type I IFNs as well as certain other cytokines and chemokines (Honda et al., 2006).
i) The TLRs use the adaptor proteins TRIF (TLR3 and 4) and MyD88 (all TLRs except
for TLR3). TRIF signals through TRAF3/TBK1/NAP1 and IKKε to phosphorylate and
thereby activate IRF3, while MyD88 activates IRF7 via IKKα (Gurtler and Bowie, 2013;
Honda et al., 2006).
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ii) Downstream of RLR activation, MAVS interacts with TRAF3 to recruit and assemble
a complex composed of TANK/NEMO/IKKε/TBK1, which phosphorylates IRF3 and
IRF7 (Belgnaoui et al., 2011). At the same time, MAVS can also interact with
TRAF2/TRAF6 to recruit IKKα/IKKβ and NEMO, resulting in activation of NFκB.
NFκB also interacts with the IFNβ promoter to drive its transcription (Belgnaoui et al.,
2011).
iii) After recognition of cytosolic DNA, STING provides a scaffold to assemble TBK1
and IRF3 in close proximity, allowing for phosphorylation of IRF3 by the TBK1 kinase
(Tanaka and Chen, 2012).
Once expressed and secreted from the cell, Type I IFNs all bind to a common Type I IFN
receptor, IFNAR (Figure 1.2). Despite sharing a single receptor, Type I IFNs can have different
cellular effects depending on the IFN subtype (α1 vs β, etc.), the cell type, and the context (i.e.
additional cytokine signals). How these pleiotropic effects are mediated is not entirely
understood, but it is known that many different signaling pathways can be activated downstream
of ligand binding to IFNAR. IFNAR is composed of IFNAR1 and IFNAR2 components, and is
expressed on most cell types (de Weerd et al., 2007). IFNAR lacks intrinsic kinase activity, and
is constitutively associated with the Janus kinases (JAKs) Tyk2 (interacts with IFNAR1) and
Jak1 (interacts with IFNAR2) (Platanias, 2005). Upon ligand binding, the JAKs phosphorylate
the receptor components and the signaling transducers and activators of transcription (STATs)
molecules (de Weerd et al., 2007). Upon phosphorylation, STATs form complexes that
translocate to the nucleus to induce the expression of hundreds of interferon stimulated genes
(ISGs) (Figure 2). These STAT complexes include STAT1, STAT2, STAT3, STAT4, STAT5
and STAT6 homodimers and heterodimers and a heterotrimer composed of STAT1, STAT2, and
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IRF9 that is known as ISGF3 (Gough et al., 2012; Levy et al., 1988; Platanias, 2005). ISGF3
binds to IFN-stimulated response elements (ISREs) present in the promoters of certain ISGs,
while other STAT complexes bind to IFN-γ-activated site (GAS) elements present in other ISGs,
with some ISGs containing both ISRE and GAS elements (Figure 1.2) (Platanias, 2005). IFNAR
signaling can also activate the p38 and MEK-ERK mitogen-activated protein kinase (MAPK)
cascades (David et al., 1995; Goh et al., 1999), as well as the phosphatidylinositol 3-kinase
(PI3K) and NFκB pathways (Uddin et al., 1995; Yang et al., 2005). The multitude of signaling
pathways that are triggered by Type I IFNs in turn result in diverse cellular responses to these
cytokines.
Further enhancing the complexity of Type I IFN responses are the hundreds of ISGs that
can be induced in a given cell type (Schoggins and Rice, 2011). Some ISGs are signaling
proteins found in the cytosol, others are transcription factors that act in the nucleus, and still
others are secreted molecules (de Veer et al., 2001). Reports that characterize the function of
ISGs tend to focus on their role in anti-viral defense. For example, 2'-5' oligoadenylate synthases
(OAS) produce 2'-5' oligoadenylates that activate RNase L, which degrades viral (as well as
host) RNA (Kristiansen et al., 2011), while the Mx proteins are GTPases that targets viral
nucleocapsids even before viral replication begins (Haller and Kochs, 2011). However, ISGs can
be involved in a plethora of additional cellular processes. These include mediating apoptosis,
transcriptional activation and repression, modulation of immune cells and cytokine expression,
protein degradation, and post-transcriptional regulation of gene expression (de Veer et al., 2001).
The diversity of ISGs allows for pleiotropic responses and the fine-tuning of host responses to
infection. Nevertheless, the functions of many ISGs are yet to be discovered.

11	
  
	
  

While Type I IFNs are strongly induced in response to pathogenic viral infection, there
are low constitutive levels of Type I IFNs that are important for homeostasis and to prime the
immune system for effective and rapid anti-microbial responses (Gough et al., 2012; Taniguchi
and Takaoka, 2001). In the absence of priming by Type I IFNs, cells have diminished responses
to Type I IFNs themselves as well as to other cytokines, including IFNγ and IL-6 (Gough et al.,
2010) (Mitani Genes Cells 2001). Constitutive amounts of IFNβ maintain high levels of STAT1,
IRF9, and IRF7 (which are themselves ISGs) (Gough et al., 2012; Gough et al., 2010; Hata et al.,
2001; Taniguchi and Takaoka, 2001). Signaling through the IFNAR complex may also provide a
docking site for STAT1, a STAT protein shared with the IFNγ and IL-6 signaling pathways in
certain cells (Taniguchi and Takaoka, 2001). With this priming, STAT1 is able to dimerize more
effectively upon IFNγ or IL-6 binding to their respective receptors (Mitani et al., 2001;
Taniguchi and Takaoka, 2001). The stimuli for constitutive Type I IFN is thought to be the
commensal microbiota (Abt et al., 2012; Ganal et al., 2012; Kawashima et al., 2013). Without
proper signals from the microbiota, mice are unable to mount an effective response against
viruses such as lymphocytic choriomeningitis virus (LCMV) and influenza virus (Abt et al.,
2012). The expression of basal Type I IFN is proposed to be IRF-independent, and instead may
require AP-1 and NFκB activity (Gough et al., 2012; Gough et al., 2010; Hata et al., 2001).
Because Type I IFNs have so many diverse effects on host physiology, both as a
consequence of anti-viral activity and as modulators of immunity, it is important to limit levels
of constitutive and induced Type I IFN. Thus, there are many levels of repression of Type I IFN
production and signaling. In unstimulated cells, IRF2 and p50 homodimers bind to the IFNβ
promoter as repressors, while the transcription factor MafB impairs the interaction of IRF3 with
coactivators (Cheng et al., 2011; Harada et al., 1989; Kim and Seed, 2010). In addition,
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molecules such as CYLD antagonize upstream pattern recognition receptors to prevent excessive
production of Type I IFN, perhaps in response to endogenous nucleic acid (Friedman et al.,
2008; Richards and Macdonald, 2011). Together, these pre-infection inhibitors maintain a
threshold constitutive level of Type I IFNs. Upon infection, these inhibitors are downregulated
and other mechanisms of negative regulation are induced, including control of receptor
expression at the cell surface, expression of negative regulatory molecules, and production of
microRNAs (miRNAs) (Ivashkiv and Donlin, 2014). Both ligand binding and additional
signaling pathways activated by other cytokines and growth factors can promote internalization
and degradation of IFNAR (de Weerd and Nguyen, 2012). Many viruses, including Hepatitis C
virus, Herpes Simplex virus, and West Nile virus, also subvert Type I IFN signaling by
downregulating receptor levels (de Weerd and Nguyen, 2012). In addition, Type I IFNs also
provide their own negative feedback by inducing suppressor of cytokine signaling (SOCS)
proteins and ubiquitin-specific peptidase 18 (USP18), which compete with STATs for binding to
IFNAR and displace JAK1, respectively (Sarasin-Filipowicz et al., 2009; Yoshimura et al.,
2007). Finally, miRNAs induced during inflammation can suppress expression of multiple
IFNAR signaling components (Gracias et al., 2013). These inhibitory mechanisms prevent the
pathology that is associated with increased Type I IFN signaling.

Dysregulation of the Type I IFN system in humans: the Type I Interferonopathies
An emerging group of diseases classified by upregulation of Type I IFNs with
inflammation and tissue damage are the Type I Interferonopathies. These disorders are proposed
to arise from either i) inappropriate activation of the Type I IFN response or ii) inadequate
negative regulation of Type I IFN production (Crow, 2011). The Type I Interferonopathies are
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genetically heterogeneous diseases including Aicardi-Goutieres syndrome (AGS),
spondyloenchondrodysplasia (SPENCD), and some forms of systemic lupus erythematosus
(SLE).
AGS affects the brain and the skin in particular, and can arise from mutations in TREX1,
SAMHD1, the three components of RNASEH2, ADAR1, and, most recently discovered, IFIH1,
which encodes MDA-5 (Crow, 2011; Crow et al., 2006a; Crow et al., 2006b; Rice et al., 2009;
Rice et al., 2014b; Rice et al., 2012). Heterozygous mutations in TREX1 and SAMHD1 can also
cause familial chilblain lupus, a form of cutaneous lupus associated with vasculopathy and
painful lesions (Crow, 2011; Rice et al., 2007). TREX1 and RNASEH2 are nucleases that are
hypothesized to remove waste nucleic acids from the cytosol. When these proteins are defective,
the accumulated host nucleic acids trigger the innate immune response (Stetson et al., 2008;
Yang et al., 2007). Specifically, Stetson et al showed that TREX1 was important for
metabolizing reverse-transcribed single stranded DNA from endogenous retroelements, which
then accrued in the cell when TREX1 was absent (Stetson et al., 2008). SAMHD1 has been
implicated in the metabolism of nucleic acid from exogenous retroviruses (Laguette et al., 2011).
This activity, which could potentially also extend to endogenous retroelements, may be
important for limiting immune reactivity. A fourth gene implicated in AGS, ADAR1, encodes an
adenosine deaminase that acts on RNA. Mutations in this gene could affect editing of specific
transcripts important for IFN production or could result in an increase in immunoreactive RNA
(Crow, 2011; Wu et al., 2011). Finally, IFIH1 encodes MDA-5, an RLR that recognizes foreign
dsRNA in the cytosol (see above). Mutant MDA-5 bound to dsRNA more avidly than WT, and
had baseline activity in the absence of exogenously added nucleic acid, indicating the presence
of endogenous dsRNA that could stimulate the mutant receptor (Rice et al., 2014b). These
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diverse mutations in AGS all promoted elevations in Type I IFN due to excess and inappropriate
recognition of endogenous or exogenous nucleic acid.
SPENCD has some clinical overlap with AGS, and some patients with SPENCD also go
on to develop SLE (Crow, 2011). Affected individuals have increased Type I IFN activity
thought to be downstream of defects in tartrate-resistant acid phosphatase (TRAP) or
osteopontin, a TRAP substrate (Briggs et al., 2011; Lausch et al., 2011). TRAP is expressed in
differentiated monocytes, macrophages, dendritic cells and osteoclasts (Hayman, 2008). This
expression coincides with the clinical manifestations of SPENCD of autoimmunity and bone
dysplasias. Osteopontin has been linked to the production of IFNα in pDCs, but the exact
mechanisms of Type I IFN upregulation in SPENCD are unclear (Shinohara et al., 2006).
SLE is a multisystem autoimmune disease associated with elevations in Type I IFNs and
autoantibodies against nucleic acids and nucleic acid-binding proteins. However, these
autoantibodies can be present before clinical symptoms appear, and the etiology of SLE is still
not well understood (Arbuckle et al., 2003). One idea is that in a genetically susceptible
individual, induction of Type I IFNs by endogenous nucleic acids or virus can precipitate disease
(Crow, 2014). In fact, there are some case reports of patients developing lupus or autoimmunity
after receiving recombinant IFNα as therapy for hepatitis C or other disorders (Gota and
Calabrese, 2003). Although these findings are merely correlative, the incidence of SLE in IFNαtreated patients is higher than the incidence in the general population, suggesting that IFNs may
play a role in SLE pathogenesis (Gota and Calabrese, 2003).
The genetics behind this disease are slowly being elucidated, but findings suggest that
SLE is actually a group of genetically distinct disorders with similar clinical phenotypes. The
strongest known susceptibility factor for SLE is complement C1q deficiency (Botto et al., 1998;
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Botto et al., 2009). Studies show that C1q inhibits IFNα production in pDCs, and that C1qdeficient patients thus have elevations in serum Type I IFN levels (Lood et al., 2009; Santer et
al., 2010). Genome-wide association studies (GWAS) and other reports also implicate genes
encoding for proteins involved in Type I IFN induction, including IRF5, IRAK1, TYK2,
TREX1, IFIH1 and MAVs (Deng and Tsao, 2010; Graham et al., 2009; Pothlichet et al., 2011;
Robinson et al., 2011). Based on these discoveries, several anti-IFNα monoclonal antibodies are
currently being tested to treat SLE in clinical trials (Kirou and Gkrouzman, 2013; Lichtman et
al., 2012). The efficacy of these treatments remain to be seen.
Despite the report of upregulated Type I IFNs in the above disorders, it is unclear
whether Type I IFNs are directly pathogenic and what their effect is on host physiology. In this
thesis, our findings show that constitutively elevated Type I IFNs can promote systemic
epithelial proliferation and cell death. This promotes accelerated wound repair, but may be
metabolically expensive and have other unintended consequences.
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Figure 1.1. Schematic of the structure and turnover of the intestinal epithelium. The
intestinal epithelium in the small intestine is formed of crypts and villi. The colonic epithelium
lacks villi but has a similar organization of crypts. Stem cells at the base of the crypts
differentiate into the 4 types of enterocytes: Paneth cells, goblet cells, absorptive enterocytes, and
enteroendocrine cells. As the stem cells differentiate, they migrate up the crypt and villi,
eventually undergoing apoptosis and shedding into the lumen.
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Figure 1.2. The Type I IFN signaling pathway. Viral and other infections are recognized by
pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), RIG-I-like receptors
(RLRs), and DNA sensors that signal to STING. The PRRs signal through a variety of different
adaptors to activate interferon regulatory factors IRF3 and 7, which translocate to the nucleus
and promote transcription of Type I IFNs. Once secreted from the cell, all Type I IFNs bind to a
common receptor, IFNAR, made of IFNAR1 and IFNAR2 subunits. These are constitutively
associated with JAK1 and TYK2 kinases. Upon ligand binding, the JAKs are activated and
phosphorylate STAT receptors, which then form stable homodimers. These can then translocate
directly to the nucleus and bind IFN-γ-activated site (GAS) elements in the promoter region of
interferon-stimulated genes (ISGs), or can bind IRF9 to form an ISGF3 complex that binds to

18	
  
	
  

IFN-stimulated response (ISRE) elements. These regulators activate the transcription of
hundreds of interferon stimulated genes (ISGs) to mediate a complex viral response.

CHAPTER 2:
Irgm1 negatively regulates systemic Type I interferon levels
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INTRODUCTION
The innate immune system is essential for initial defense against pathogens. Its molecular
mediators include secreted molecules that signal to surrounding and distant cell types, as well as
intracellular proteins that protect an infected cell from succumbing to or spreading infection. One
family of intracellular innate immune proteins is the IFNγ-inducible p47 GTPases. Of these,
Immunity-related GTPase family M protein 1 (Irgm1), has been shown to be integral for host
defense against multiple intracellular protozoans and bacteria. However, it is unclear whether
Irgm1 acts directly in a cell-autonomous manner to protect cells from infection or whether its
protection is mediated through effects on immune function.
The Irgm1 knockout mouse was created by Gregory Taylor’s group in 2001. They
showed that Irgm1-/- mice were highly susceptible to infection with Toxoplasma gondii and
Listeria monocytogenes compared to WT mice (Collazo et al., 2001). In short succession,
Irgm1-/- mice were also shown to be susceptible to Mycobacterium tuberculosis (MacMicking et
al., 2003), Mycobacterium avium (Feng et al., 2004), Trypanosoma cruzi (Santiago et al., 2005),
Salmonella typhimurium (Henry et al., 2007), and Chlamydia muridarum (Coers et al., 2008).
Different theories were presented as to how Irgm1 protected mice from these diverse
intracellular pathogens. One idea was that Irgm1 aided in the maturation of pathogen-containing
phagosomes and their fusion with the lysosome (MacMicking et al., 2003). Further studies built
upon this idea, implicating Irgm1 and its human homologue IRGM in autophagosome formation
and autophagy-mediated pathogen clearance (Singh et al., 2010). A second hypothesis was that
infection in Irgm1-/- mice induced lymphopenia and pancytopenia, resulting in death of the mice
(Feng et al., 2004; Feng et al., 2008a; Feng et al., 2008b). This defect was associated with
impaired expansion of Irgm1-/- hematopoietic stem and progenitor cell populations after infection
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(Feng et al., 2008a). The mechanism of this was thought to be IFNγ and STAT1-dependent
(Feng et al., 2008b; King et al., 2011). In addition, studies showed increased IFNγ-induced
autophagy-related cell death specifically in activated CD4+ T cells in Irgm1-/- mice (Feng et al.,
2008b; Xu et al.). Since CD4+ T cells play an important role in experimental autoimmune
encephalomyelitis (EAE), a mouse model of multiple sclerosis, the death of these cells in
Irgm1-/- mice promoted resistance to EAE (Xu et al.). Another school of thought proposed that
Irgm1 played a role in the regulation of macrophage motility (Henry et al., 2007; Henry et al.,
2010). Irgm1-deficient macrophages were unable to suppress intracellular growth of S. typhii,
and had defects in adhesion and motility after stimulation with IFNγ due to decreased actin
remodeling (Henry et al., 2007). The different mechanisms of susceptibility in Irgm1-/- mice
observed by different groups might be accounted for by variance in genetic background,
microbiota composition, and/or diverse reagents such as the use of tagged Irgm1 constructs
versus antibodies.
The localization of Irgm1 with IFNγ treatment and upon microbial entry also remains
somewhat controversial. Irgm1 was found to localize to the Golgi membranes as well as late
endosomal and lysosomal compartments in IFNγ-treated cells (Martens et al., 2004; Zhao et al.,
2010). Localization to the endolysosomal system required activity of the nucleotide binding site
of Irgm1, while localization to the Golgi did not. However, the C-terminal amphipathic helix of
Irgm1 was required for localization to both compartments (Martens et al., 2004; Zhao et al.,
2010). In addition, palmitoylation of a cluster of cysteines near the amphipathic helix also
contributed to appropriate localization to cellular membranes (Henry et al., 2014). Notably, Zhao
et. al. also found that both N- and C-terminal enhanced green fluorescent protein (EGFP) tags
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caused mislocalization of Irgm1, cautioning against the use of these reagents that may have
confounded previous studies (Zhao et al., 2010).
Many of the pathogens to which Irgm1 mediates resistance establish intracellular
compartments, such as bacterial phagosomes, apicomplexan parasitophorous vacuoles, and
chlamydial inclusion bodies. Irgm1 has been shown to translocate to mycobacterial phagosomes
in murine macrophages and has been found on Listeria monocytogenes vacuoles (MacMicking et
al., 2003; Shenoy et al., 2007; Tiwari et al., 2009). Tiwari et al showed that this localization was
dependent on the recognition of host phosphoinositide lipids phosphatidylinositol-3,4,5trisphosphate and phosphatidylinositol-3,4-bisphosphate on the nascent phagosome (Tiwari et
al., 2009). In this report, the amphipathic helix of Irgm1 was shown to be required for binding to
the phosphoinositides. Irgm1 was then found to bind to snapin, a SNARE adaptor protein, and
may regulate its assembly activity or phosphorylation to recruit dynein motor complexes(Tiwari
et al., 2009). These motor complexes would then allow trafficking of the phagosome along
microtubules to maturing autolysosomes, which could then promote membrane fusion and
lysosomal destruction of the mycobacteria (Cai and Sheng, 2011).
In direct contrast to these observations, Springer et al did not detect association of Irgm1
with either the listerial or mycobacterial phagosome in mouse macrophages or primary
fibroblasts (Springer et al., 2013). They found that there are both a short and a long isoform of
Irgm1 that are derived from differential splicing, and developed new anti-serum against these
isoforms. They discovered that both isoforms can be found in the Golgi, but the short isoform
failed to colocalize with the endolysosomal compartment. Both isoforms were found to weakly
associate with mitochondrial membranes as well. Springer et al suggested that reasons for these
discrepancies in localization was that in contrast to previous reports, their study distinguished
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between extracellular and intracellular organisms and did not use tagged constructs that may
have been mislocalized (Springer et al., 2013).
In addition, Irgm1 has not been found to colocalize to parasitophorous vacuoles (PV).
Hunn et al proposed that Irgm1 instead regulates other IRG proteins such that they can be
recruited to the PV membrane (PVM) (Hunn et al., 2008). There are potentially 23 members of
the p47 GTPase (IRG) family in the mouse, 21 of which may be functional and 6 of which have
been well-studied (Bekpen et al., 2005; Bekpen et al., 2009) Out of these, three are GMS
GTPases (possess a methionine in the conserved P-loop G1 motif of the nucleotide binding site),
while the rest are canonical GKS GTPases (have a lysine in that site) (Boehm et al., 1998). The
murine GMS GTPases (Irgm1, Irgm2, and Irgm3) are thought to regulate the other GKS
GTPases by interacting with GKS proteins in the GDP-bound state and inhibiting GTP binding
(Hunn et al., 2008). This would prevent the GTP-dependent oligomerization of GKS proteins and
the formation of cytoplasmic aggregates. At the PVM, there is an absence of GMS proteins,
which allows for the GKS proteins to take up GTP and be activated at this site (Hunn et al.,
2008). These GKS effectors can directly disrupt PV membranes, eventually leading to necrotic
death of the infected cell (Ling et al., 2006; Martens et al., 2005; Zhao et al., 2009). A more
recent study proposed that the localization of Irgm1 and Irgm3 to host membranes prevented
stable association of GKS and guanylate-binding proteins (GBPs), a second family of IFNγinduced GTPases, to these organelles (Haldar et al., 2013). The absence of GMS proteins on PVs
or artificially stripped lipid droplets indicated the presence of “non-self”, and resulted in the
recruitment and formation of GKS and GBP oligomers to these membranes (Haldar et al., 2013).
Based on these most recent studies, it would appear that Irgm1 is not directly involved in cell-
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autonomous defense against microbes but instead is a regulator of GTPase activity located on
intracellular host membranes.
The human homologue of Irgm1, IRGM, is of clinical interest because of its association
with susceptibility to tuberculosis and Crohn’s disease, but the two proteins have limited
similarity. IRGM is 181 amino acids (aa) in length, while Irgm1 is 409aa long. Out of 174aa that
align by protein blast, there is only 57% identity. In addition, human IRGM does not appear to be
IFNγ-inducible (Bekpen et al., 2005). Therefore, we recommend caution when extrapolating data
from mouse studies to human and vice versa until further knowledge is acquired.
There are 23 p47 GTPases in the mouse, whereas the human genome only has one single
full-length gene (IRGC) on chromosome 19 and an expressed, truncated gene on chromosome 5
(IRGM) (Bekpen et al., 2005). Bekpen et al propose that this difference in numbers of p47
GTPase family members is due to differences in the evolutionary history of these genes (Bekpen
et al., 2009). The IRG family is at least as old as bony fish but is not present in invertebrates
(Bekpen et al., 2005). The genomic sequences and positioning of the mouse genes imply a
succession of duplication and divergence over time (Bekpen et al., 2005). In the human lineage,
Bekpen et al suggest that the IRGM gene became nonfunctional approximately 40 million years
ago with the integration of an Alu repeat that disrupted the ORF, and accumulation of stop
codons and frameshift mutations, resulting in pseudogene copies in Old World and New World
monkeys. However, IRGM was then “resurrected” in perhaps a truncated form about 20 million
years ago in human ancestors (Bekpen et al., 2009). At this time, there was an integration of the
ERV9 retrotransposon element that serves as the IRGM promoter, the introduction of a new start
codon, and the loss of a stop codon (Bekpen et al., 2009). There are 5 splicing isoforms of human
IRGM, a-e, but whether these have different functions is unknown. IRGC, on the other hand, was
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probably conserved during this time, as it is very similar to murine Irgc; they are both
constitutively expressed in the testis and not IFNγ-inducible (Bekpen et al., 2005).
Akin to murine Irgm1, the function of IRGM is still being uncovered. Knockdown
studies in human macrophages suggested that IRGM was involved in autophagy and important
for autophagy-induced mycobacterial clearance (Singh et al., 2006; Singh et al., 2010). IRGM
has also been shown to bind autophagy proteins and the inner mitochondrial membrane lipid
cardiolipin to induce mitochondrial fission and autophagy (Gregoire et al., 2011; Petkova et al.,
2012; Singh et al., 2010; Tiwari et al., 2009). Four autophagy-related proteins have been found to
interact with IRGM: ATG5, ATG10, MAP1LC3C, and SH3GLB1 (Gregoire et al., 2011). In
comparison, Irgm1 has been shown to be dispensable in IFNγ-induced autophagy in
macrophages (Matsuzawa et al., 2012). Better reagents to study IRGM are necessary to fully
characterize its function in human cells.
IRGM polymorphisms have been linked to susceptibility to Crohn’s disease (CD), but it
is not clear whether risk is due to upregulation or downregulation of expression of IRGM, or
change of function of the gene product. CD is a chronic inflammatory bowel disease (IBD) that
is characterized by inflammation of the gastrointestinal tract, resulting in damage to the mucosa.
Genome-wide association studies have identified dozens of susceptibility alleles that are linked
to CD, including IRGM (McCarroll et al., 2008; Parkes et al., 2007). The risk allele rs13361189
is in perfect linkage disequilibrium with a 20kb deletion upstream of the IRGM gene, but this
resulted in upregulation of IRGM in some cell types and downregulation of expression in others
(Huett et al., 2009; McCarroll et al., 2008). Further complicating the matter, Brest et al showed a
role for a microRNA (miRNA) that differentially regulated the risk and protective haplotypes
(Brest et al., 2011). Their results demonstrated that miR-196 bound strongly to downregulate the
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protective haplotype but not the risk haplotype. MiR-196 also had enhanced expression in
inflamed tissue. Taken together, these findings suggested a model in which there was
upregulation of IRGM in carriers of the risk variant because miR-196 could not effectively bind
its target site, especially in inflamed areas (Brest et al., 2011).
In addition, polymorphisms in IRGM have been linked to protection against tuberculosis
(Bahari et al., 2012; Che et al., 2010; Intemann et al., 2009). The IRGM variant rs9637876 was
associated with increased levels of expression and was protective against M. tuberculosis
(Intemann et al., 2009). Similar to its murine homologue, IRGM could thus be involved in
resistance against mycobacterium. This could also provide an explanation for the evolutionary
preservation of gene variants resulting in upregulation of expression that increased the risk for
IBD: these variants could be protective against tuberculosis, a widespread infection.
Based on these findings, we were interested in discovering the function of Irgm1,
particularly at mucosal surfaces, which would advance our knowledge about why
polymorphisms in IRGM influence susceptibility to Crohn's disease in the intestine and
tuberculosis in the lung. We found that Irgm1-/- mice had systemic elevations in Type I
interferons, a family of anti-viral cytokines. Our findings suggest that Irgm1 functions by
influencing the innate immune cytokine environment.
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MATERIALS AND METHODS
Mice
All experimental procedures were performed under approval by Washington University's Animal
Studies Committee. Irgm1-/- mice were provided by Dr. Gregory A. Taylor (Duke University,
Durham, NC; (Collazo et al., 2001)). Ifnar-/- mice are deficient in Ifnar1 (Muller et al., 1994).
These mice were provided by Dr. Robert D. Schreiber and Dr. Herbert W. Virgin (Washington
University in St. Louis, St. Louis, MO; (Thackray et al., 2012)). All mice were re-derived into
our enhanced barrier facility and were fully backcrossed to a C57BL/6 background. For
experiments with knockout mouse lines, heterozygote breeding pairs were used to obtain WT
controls.

Micro-computed tomography (MicroCT)
MicroCT of the femur was performed on 12 week-old WT and Irgm1-/- mice as previously
described (DeSelm et al., 2012).

Toxoplasma gondii infection
Toxoplasma gondii cysts (Type II Prugniaud strain) were obtained from the brains of CBA/J
mice injected with T. gondii 3-6 months prior. The brains were homogenized, fixed with 3%
formaldehyde and cysts were stained with lectin-FITC. The suspension was pipetted onto slides
and the number of cysts counted. C57BL/6 and Irgm1-/- mice were then infected orally with 7
cysts of T. gondii. Weight loss and lethality were monitored daily for 30 days.
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Enzyme-linked immunosorbent assay
The mouse IFNγ "Femto-HS" High Sensitivity Enzyme-linked Immunosorbent Assay (ELISA)
kit (Affymetrix eBioscience) was used to measure levels of IFNγ in serum (diluted 1:4 in assay
diluent) and tissue homogenate (diluted 1:2).

Laser Capture Microdissection and Microarray Analysis
Small intestinal sections were harvested and pinned flat in methacarn fixative (60% absolute
methanol, 30% chloroform, 10% glacial acetic acid) for 2 hours. Tissue was then washed and
stored in 70% ethanol until blocked in agar. After paraffin embedding, unstained sections were
cut onto uncharged slides. Slides were deparaffinized and stained with methyl green for
visualization of nuclei. The intestinal epithelium only was captured using a PixCell II LCM
system (Arcturus; 7.5µm laser spot) and CapSure HS LCM caps (Arcturus). Total cellular RNA
was extracted using PicoPure RNA isolation kit (Arcturus). RNA was amplified and synthesized
into cDNA. Microarray analysis was performed on 4x44K mouse whole genome microarrays
(Agilent) as previously described (Cadwell et al., 2010).

Type I IFN bioassay
Type I IFN bioassay was performed as previously described (Newby et al., 2007). Briefly, L929
cells were plated at 3.5x105 cells/mL in 12-well plates and rested at 37°C for 4h, then incubated
with 1:2 dilutions of serum, tissue homogenate, cell lysates, or plasma and a range of units of
recombinant murine IFN-αA (PBL Interferon Source) and IFN-β (PBL Interferon Source) for
24h at 37°C. Neutralizing anti-IFNα (clone TIF-3C5) and anti-IFNβ1 (clone HDβ-4A7) were
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pre-incubated with sample or positive control IFN for 1h at room temperature before addition to
L929 cells (t0). Neutralizing anti-Ifnar1 antibody (Leinco Technologies, clone # MAR1-5A3)
was administered to wells at 3µg/mL at t0 and 1µg/mL at 16-18h after t0. 24h after t0, treatment
was aspirated and L929 cells were washed 2X with phosphate-buffered saline (PBS). Green
fluorescent protein (GFP)-tagged vesicular stomatitis virus (VSV) (kindly provided by Dr. John
Rose, Yale University, New Haven, CT) was added to L929 cells at 10 multiplicities of infection
(MOI), and incubated for an additional 10-12h. L929 cells were then trypsinized, washed with
FACS buffer (PBS + 3% bovine serum albumin + 0.01% sodium azide) and fixed with BD
Cytofix/Cytoperm (BD Biosciences). Cells were run through a flow cytometer and the median
fluorescence intensity (MFI) determined. Standard curves with murine recombinant IFNαA were
run for each experiment and the level of anti-viral activity was calculated relative to WT
samples.

Pan-anti-IFNα and anti-IFNβ antibodies
As will be reported in further detail elsewhere, anti-IFNα (clone TIF-3C5) is an Armenian
hamster monoclonal antibody (mAb) that binds to and neutralizes in vitro activity of all available
murine IFN-α subtypes (IFN-α A, 1, 4, 5, 11, and 13), as assessed by quantitating i) induction of
Stat1 phosphorylation; ii) MHC class I induction; and iii) antiviral activity (using a cytopathic
effect assay and Vesicular Stomatitis Virus). The TIF-3C5 mAb does not bind murine IFNγgamma or IFNβ, nor does it affect functional activity of these IFN species. Anti-IFNβ (clone
HDβ-4A7) is a murine IgG2a mAb that binds and neutralizes murine IFNβ but not murine IFNα
species or IFNγ using identical assays as described above (Sheehan et al, unpublished
observations).
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Influenza A infection
For influenza infection, 8-10 week-old male mice were anesthetized with ketamine and infected
intranasally with 5000 pfu of influenza A/WSN/33 virus (generated from cDNA as previously
described (Neumann et al., 1999), Morales et al, in submission). Mice were weighed and
inspected daily. Mice with greater than 30% weight loss were sacrificed as per protocol. Viral
titers were determined from lung homogenate of the right lobes by plaque assay (using MDCK
cells).

RNA isolation and Quantitative real-time PCR
Tissue was snap frozen in liquid nitrogen and RNA was extracted using the Nucleospin RNA II
purification kit (Macherey-Nagel). RNA was extracted from in vitro intestinal epithelial cultures
by directly adding RA1 buffer from the RNA purification kit and proceeding with the remainder
of the protocol. cDNA was synthesized using SuperScript III (Invitrogen). Gene expression was
quantified using SYBR Green reagents (Clontech) on an Eppendorf Mastercycler. Δ Ct values
were calculated relative to GAPDH.

Histology and immunofluorescence of the lung
For haematoxylin and eosin (H+E)-stained sections of lung, the lung was inflated using 1mL of
10% neutral-buffered formalin through the trachea. Tissue was fixed at room temperature (RT)
overnight. Tissue was then washed in PBS, then 35%, 45%, and 70% ethanol for 15 minutes
each at room temperature before storage in 70% ethanol at 4°C. Lung tissue was then embedded
in paraffin, cut into slides, and then H+E-stained. The area of cellular aggregates and total lung
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parenchyma was measured from digital images using ImageJ software. For immunofluorescence,
mouse lung was inflated using 2mL of 1:1 PBS:OCT compound (Tissue-Tek). Tissue was then
immediately frozen in cassettes surrounded by OCT. Frozen sections were cut on a cryostat and
stored at -80°C. When used for staining, slides were dried for 2-3 minutes at RT, then fixed in
cold methanol or cold 4%PFA for 5 minutes. After washing with PBS and blocking with 1%
BSA and 0.1% Triton X-100 in PBS, slides were incubated with primary antibody for 1hr at RT
or overnight at 4°C. Primary antibodies: anti-CD45 Alexa-488 (BD Pharmingen clone 30-F11).
FITC-conjugated anti-B220 and unconjugated anti-B220 (Biolegend, clone RA3-6B2). AntiCD19-PE (Biolegend, clone 6D5). Anti-CD3e Alexa-647 (Biolegend, clone 145-2C11). AntiCD11c Alexa-647 (Biolegend, clone N418). FITC-conjugated anti-Gr1 (Biolegend, clone RB68C5). Anti-Siglec H-PE (Miltenyi-Biotec, clone 551.3D3). Unconjugated anti-CD11b (BD
Pharmingen, clone M1/70).

Bone marrow-derived dendritic cell (BMDC) experiments
Bone marrow was isolated from mouse femurs and tibias. Bone marrow cell suspension was
plated on non-tissue culture-treated petri dishes in BMDC media at 37°C (RPMI with 10% FBS,
1% penicillin-streptamycin, 2% L-glutamine, 2% GM-CSF supernatant, 1mM sodium pyruvate,
0.1mM nonessential amino acids, 50uM beta-mercaptoethanol). After 4 days, cells were replated,
and on day 6, media was changed. Cells were treated with polyI:C on day 7 after initial plating
and cells harvested for RNA on day 8. Cell lysates and cell supernatants for Type I IFN bioassay
were also isolated on day 8.
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Intestinal epithelial spheroids
Colonic and small intestinal crypts were isolated from mice and cultured in a 3D-Matrigel as
previously described (Miyoshi et al., 2012; Miyoshi and Stappenbeck, 2013). Briefly, 1-2cm of
tissue was harvested, minced into a fine homogenate with scissors, and Type I collagenasetreated (Invitrogen) in 37°C with vigorous pipetting until epithelial crypts were dissociated from
tissue. Crypts were suspended in Matrigel basement membrane matrix (BD Biosciences) and
incubated with 50% conditioned media from L-cells containing Rspo3, Wnt3a and Noggin (LWRN). Crypt cells grew into spheroids, which were passaged every 2-4 days.

Ifnar surface expression measurements
Whole bone marrow was isolated from WT, Irgm1-/- and Irgm1-/- Ifnar-/- mice. After red blood
cell lysis and washing, cells were either left unstained, or stained with anti-Ifnar-APC antibody
(Biolegend, clone MAR1-5A3) or isotype control (mouse IgG1). Cells were run through a
FACSCalibur flow cytometer and data analyzed using FloJo software.

Clodronate liposome macrophage depletion
250µL of clodronate or control liposomes (Encapsula) were delivered intravenously (i.v.) to WT
and Irgm1-/- mice on d0 and d3. Mice were sacrificed on d6. Blood was obtained using cardiac
puncture and kept at 4°C overnight. Blood was then spun down and serum was extracted and
stored at -20°C.
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Antibiotic treatment
Mice were given antibiotics dissolved in Kool-Aid or Kool-Aid alone (control) instead of
drinking water for two weeks. Antibiotics: 500mg ampicillin, 250mg vancomycin, 500mg
neomycin-sulfate, 500mg metronidazole, 10g grape Kool-Aid in 500mL water, sterile filtered
through a 0.22um filter. Mice were sacrificed on day 15 and serum and tissue was harvested.

Statistics
GraphPad Prism software (version 6) was used to perform all statistical analyses unless
otherwise specified.
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RESULTS
Irgm1-/- mice were resistant to flu infection due to heightened baseline Type I IFNs
We first re-derived Irgm1-/- mice into our enhanced barrier facility (Cadwell et al., 2010),
and fully backcrossed them to a C57BL/6 (B6) background. We implemented a heterozygote
breeding scheme to obtain littermate controls. Irgm1-/- mice bred at near Mendelian ratios
(Figure 2.1A) and displayed no overt signs of ill health (observed up to the age of 13 months).
However, we noticed that Irgm1-/- mice had consistently smaller mass than their wild-type (WT)
littermates at multiple ages (Figure 2.1B). However, bone volume fractions and multiple other
bone parameters were comparable between Irgm1-/- and WT mice, indicating the smaller size of
Irgm1-/- mice was not due to a bone-intrinsic defect (Figure 2.1C, Table 2.1).
Irgm1-/- mice bred outside our institutional facility have previously been shown to be
susceptible to multiple intracellular pathogens, including Mycobacterium tuberculosis,
Toxoplasma gondii, and Listeria monocytogenes (Coers et al., 2008; Collazo et al., 2001; Feng et
al., 2004; Henry et al., 2007; MacMicking et al., 2003; Santiago et al., 2005). We found that our
re-derived Irgm1-/- mice were still highly susceptible to T. gondii infection (Figure 2.1D).
To determine the function of Irgm1 at mucosal surfaces, we performed whole genome
microarray analysis of RNA from the intestinal epithelium of wild-type (WT) and Irgm1-/- mice.
This was accomplished using laser capture microdissection, a technique that allows for RNA
isolation from specific areas of tissue on a slide under microscopic guidance (Emmert-Buck et
al., 1996). Functional gene annotation analysis of 461 genes that were enriched greater than 2fold in Irgm1-/- epithelium identified significant elevations in "Interferon-mediated immunity"
genes (Bonferonni value = 2.47 E-13) (Figure 2.2). These genes include those stimulated by
Type I Interferon (IFN) (IFNαs, β, and other subtypes) as well as those induced by Type II IFN
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(IFNγ). Previous studies have found that Irgm1-/- mice have elevated serum IFNγ ((King et al.,
2011). However, Irgm1-/- mice bred in our enhanced barrier facility did not have detectable
serum IFNγ, and organ levels of IFNγ were not different in wild-type (WT) C57BL/6 and
Irgm1-/- mice (Figure 2.3). Instead, manual inspection of highly-enriched genes in our
microarray data set revealed elevations in IFN-stimulated genes (ISGs), a group of transcripts
that are expressed downstream of Type I IFN signaling (Table 2.2). In addition, we found that
Type I IFNs were elevated in the serum and lung homogenate of uninfected Irgm1-/- mice
(Figure 2.4A). The systemic elevation of Type I IFNs in Irgm1-/- mice has not been previously
reported and was unusual, as these cytokines are typically only transiently elevated upon
infection, with constitutive levels in the serum and tissues barely detectable by current assays
(Gough et al., 2012). To measure Type I IFN, we used a bioassay system in which we incubated
serum of Irgm1-/- and WT mice with L929 cells, then subsequently infected the cells with a GFPtagged vesicular stomatitis virus (VSV; Figure 2.5A and (Newby et al., 2007)). We then used
flow cytometry to measure the levels of VSV-GFP per cell, which negatively correlated with the
amount of anti-viral activity in the mouse sample (Figure 2.5A). All Type I IFNs signal through
the Type I IFN receptor (Ifnar), which is a heterodimer composed of two subunits, Ifnar1 and
Ifnar2 (de Weerd et al., 2007). The addition of an antibody against Ifnar1 neutralized the antiviral activity found in Irgm1-/- serum. A pan-anti-IFNα antibody, but not an anti-IFNβ1 antibody,
was also able to neutralize the anti-viral activity present in the serum of Irgm1-/- mice, showing
that these mice have elevated systemic levels of IFNα (Figure 2.4B and Figure 2.5B). Type I
IFNs were not present at elevated levels in Irgm1+/- mice, suggesting that a complete loss of
Irgm1 function was required to induce these cytokines (Figure 2.4C). Increased Type I IFNs in
Irgm1-/- mice could be found as early as day 7 and as late as12 months of age (Figure 2.4D-E).
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We then investigated whether these elevated Type I IFN levels were functional, and
therefore examined the response of Irgm1-/- mice to influenza A infection. Irgm1-/- mice were
resistant to influenza A infection at doses that were lethal to 50% of WT mice (Figure 2.6A).
Interestingly, viral titers were not different in the lung at day 3 between WT and Irgm1-/- mice
(Figure 2.6B). As expected, systemic Type I IFNs induced the expression of interferonstimulated genes (ISGs) such as Oas2 and Mx2 in numerous tissues, including the lung (Figure
2.6C-D). These results indicated that high Type I IFN levels in Irgm1-/- mice chronically
stimulated gene expression with consequent changes in susceptibility to infection.

Irgm1-/- mice had lymphoid aggregates in the lung parenchyma dependent on Type I IFN
signaling
To investigate possible mechanisms of anti-viral defense, we examined the histology of
the lungs of WT, Irgm1-/- and Irgm1-/- Ifnar-/- mice. We found the presence of aggregates of
lymphoid-appearing cells in Irgm1-/- mice but not WT mice, even without flu infection (Figure
2.7A-B). Aggregates were present in 100% of Irgm1-/- mice, but only in about one-third of
Irgm1-/- Ifnar-/- mice (Figure 2.7B). The area of these aggregates was also decreased in Irgm1-/Ifnar-/- mice (Figure 2.7C). Immunofluorescence staining revealed that the aggregates were
composed of CD45+ leukocytes (Figure 2.8A). Specifically, there was a core of B220+ cells,
most of which were CD19+, suggesting that these were B cells, surrounded by CD3+ T cells
(Figure 2.8B-C). There were also CD11c+ and Gr1+ cells scattered throughout the aggregate
(Figure 2.8D-E). The plasmacytoid dendritic cell marker Siglec-H was present on some but not
all B220+ cells (Figure 2.10F). There were very few CD11b+ cells in the aggregates of Irgm1-/mice (Figure 2.8G). These staining results suggested that the lymphoid aggregates in Irgm1-/36	
  
	
  

lungs were composed of mostly B cells with some T cells and dendritic cells, and possibly
macrophages. These immune cell populations may have played a role in anti-viral defense
against flu infection.

Type I IFNs were elevated in lung, serum, and bone marrow of Irgm1-/- mice, but mRNA levels of
IFNα and IFNβ were unchanged between multiple tissue types
We next sought to determine the source of the Type I IFNs in Irgm1-/- mice. Using the
bioassay system, we assayed various tissue and blood cell types for elevations in these cytokines.
Anti-viral activity was not detected in the spleen, colon, or bone marrow of Irgm1-/- mice
(Figure 2.9A-B). However, anti-viral activity was found in the lung homogenate of Irgm1-/- mice
in addition to the serum (Figure 2.9C-D). The plasma fraction of blood, not red or white blood
cell lysates, contained the anti-viral activity, implying that it is not cells circulating within the
bloodstream that are releasing the interferons (Figure 2.9E). Cells within the lung may be
responsible for elevated levels of Type I IFNs in Irgm1-/- mice.
However, when we examined mRNA expression using primers against IFNβ1, and a panIFN-α primer set, we did not observe any significant differences in lung, small intestine, colon,
spleen, or bone marrow (Figure 2.10A-B). This suggests either that 1) Irgm1 negatively
regulates Type I IFNs at the post-transcriptional level, or 2) the interferon that was elevated is of
a type that was not detected using our primer set.

Irgm1-deficient dendritic cells and epithelial cells did not have enhanced sensitivity to polyIC.
We wondered whether cells lacking Irgm1 had enhanced sensitivity to Type I IFNinducing stimuli. We tested WT and Irgm1-deficient bone marrow-derived dendritic cells
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(BMDCs) for production of Type I IFNs upon polyinosinic:polycytidylic acid (polyI:C)
treatment. We chose to examine these cell types because DCs are important producers of Type I
IFNs during anti-viral responses (Asselin-Paturel and Trinchieri, 2005). We found no difference
between Irgm1-/- and WT BMDC expression of pan-IFN-α, IFN-β1, or IFN-α4 in response to
increasing doses of polyI:C (Figure 2.11A-C). ISG expression was also comparable in both WT
and Irgm1-deficient BMDCs (Figure 2.11E-F). In addition, Type I IFN activity in BMDC
culture supernatant and cell lysate was similar as measured by bioassay (Figure 2.12A-B).
We also assessed the sensitivity of non-hematopoietic cells, intestinal epithelial
spheroids, to polyI:C treatment. Again, we did not discern any differences in IFNβ1 or pan-IFNα
expression in response to polyI:C (Figure 2.13A-B). Together, these results suggest that neither
bone marrow dendritic cells nor intestinal epithelial cells deficient in Irgm1 had enhanced
sensitivity to dsRNA stimuli.

Cells deficient in Irgm1 did not have altered cell surface expression of Ifnar
One possible reason for increased levels of circulating Type I IFNs is diminished cell
surface expression of the Type I IFN receptor, Ifnar. Lower expression of Ifnar would result in
less Type I IFN being bound to the cell and/or internalized, resulting in higher measurable levels
of Type I IFNs. We measured Ifnar cell surface expression on whole bone marrow cells and
found that there was no difference in levels of expression between WT and Irgm1-deficient bone
marrow (Figure 2.14). In contrast, bone marrow from Irgm1-/- x Ifnar-/- mice had low Ifnar
expression, as expected (Figure 2.14C-D).
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T and B lymphocytes were not involved in the production of Type I IFNs in Irgm1-/- mice.
Since Irgm1 is highly expressed in naïve T lymphocytes (Immgen.org, Figure 2.15), and
both T and B cells were present in lymphoid aggregates in Irgm1-/- mice, we investigated
whether these lymphocytes were involved in Type I IFN overproduction in Irgm1-deficient mice.
We crossed Irgm1-/- mice to Rag1-/- mice, which lack both mature T and B cells. Irgm1-/- Rag1-/mice still maintained elevated serum levels of Type I IFNs, suggesting that T and B
lymphocytes, and the adaptive immune response, were not involved in overproduction of Type I
IFNs in Irgm1-deficient animals (Figure 2.16). As expected, Irgm1+/-Rag1-/- mice had levels of
Type I IFNs similar to WT (Figure 2.16).

Clodronate liposome-mediated depletion of macrophages decreased Type I IFN serum levels in
Irgm1-/- mice.
Macrophages are an additional candidate cell type for Type I IFN production (Kim et al.,
2012; Kumagai et al., 2007). We depleted tissue macrophages using intravenous (i.v.) injection
of clodronate liposomes (Van Rooijen and Sanders, 1994). After 2 injections once every 3 days,
Irgm1-/- mice injected with clodronate liposomes had decreased levels of Type I IFNs compared
to Irgm1-/- injected with control liposomes (Figure 2.17A-C). At this time, macrophages were
depleted in the liver but not in the kidney (Figure 2.17D and data not shown). Clodronate
liposome-mediated depletion of macrophages in WT mice did not have a significant effect on
serum Type I IFN levels (Figure 2.17A-B). These findings demonstrate that liver macrophages
played an important role in Type I IFN production in Irgm1-/- mice.
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Antibiotic treatment did not affect Type I IFN production in Irgm1-/- mice
A further question was whether the Type I IFNs were being produced in response to gut
microbial stimuli in Irgm1-/- mice. To address this possibility, we treated mice with a broadspectrum antibiotic regimen of vancomycin, neomycin, ampicillin, and metronidazole for 2
weeks. We found that antibiotic treatment did not diminish Type I IFN levels in Irgm1-deficient
mice, and in fact may have increased Type I IFNs (Figure 2.18). This suggests that the microbial
stimuli for Type I IFNs in Irgm1-/- mice were not susceptible to this antibiotic regimen.
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DISCUSSION
Irgm1 has previously been reported to have a variety of roles in the immune system, but
its exact function within the cell is controversial. We found that Irgm1-/- mice in our enhanced
barrier facility had elevated circulating Type I IFNs even in the absence of pathogenic viral
infection.
Notably, the previous observations regarding the susceptibility of Irgm1-/- mice to
intracellular pathogens are compatible with the known effects of Type I IFNs. First, Type I IFNs
have been shown to be detrimental to the host during infection with L. monocytogenes, M.
tuberculosis, and C. muridarum (Auerbuch et al., 2004; Carrero et al., 2004; O'Connell et al.,
2004; Qiu et al., 2008; Stanley et al., 2007). The mechanisms for this process have not yet been
well elucidated, but previous studies have implicated loss of Ifnar signaling with changes in
macrophage cytokine production and IFNγ responsiveness in these infectious systems (Auerbuch
et al., 2004; Rayamajhi et al., 2010a; Rayamajhi et al., 2010b). In addition, reports on L.
monocytogenes showed that Type I IFNs increased sensitization of lymphocytes to cell death
(Carrero et al., 2004, 2006), similar to what was observed in Irgm1-/- mice upon infection (Feng
et al., 2004; Feng et al., 2008b). This finding was supported by further studies using vesicular
stomatitis virus (VSV), polyinosinic:polycytidylic acid (polyI:C), a synthetic double-stranded
RNA TLR3 agonist and R848, an imidazoquinoline TLR7/8 agonist, all of which stimulate Type
I IFN production in vivo (Kamphuis et al., 2006). Subsequently, two reports published in 2009
demonstrated that Type I IFNs promoted exit of hematopoietic stem cells (HSCs) from the
quiescent state, resulting in subsequent proliferation and finally functional exhaustion of the
HSCs and decreased production of mature blood cells (Essers et al., 2009; Sato et al., 2009).
HSC function was compromised after 2-3 weeks of chronic Type I IFN production (Essers et al.,
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2009; Sato et al., 2009). These results are comparable timeline-wise to the lymphopenia that was
observed in Irgm1-/- mice after M. avium infection (measured 4 weeks after infection) (Feng et
al., 2004). Although the authors did not examine Type I IFN levels, M. avium infection may have
stimulated production of those cytokines above even baseline amounts in Irgm1-/- mice, resulting
in HSC exhaustion and lymphopenia. The report by King et al in 2011 demonstrated that even in
the absence of overt infection, aged 12 month-old Irgm1-/- mice had reduced numbers of HSCs
(King et al., 2011). While they focused on the importance of IFNγ in this effect, their results
suggested a significant and unexamined role for Type I IFNs in mediating HSC dysfunction. For
example, their results showed elevated levels of IFN-stimulated genes in HSCs from Irgm1-/mice compared to WT mice. However, out of 19 genes listed, only 15 were classified as
interferon-stimulated genes by the Interferome database and out of those genes, 3 were classified
as only being induced by Type I IFNs, not Type II. In addition, they only saw partial rescue of
HSC defects in Irgm1-/- mice with deficiency in IFNγ receptor, but a full rescue in Irgm1-/- x
Stat1-/- mice (King et al., 2011). Thus, it is possible that the previous findings regarding the role
of Irgm1 in host defense are attributable to elevated Type I IFNs that we observed in Irgm1-/mice. This would suggest that Irgm1 does not act in a cell-autonomous manner to mediate
protection, but by modulating the innate immune system.
Our data suggests that not all cell types are required for the production of Type I IFNs in
Irgm1-/- mice. In particular, loss of T and B cells did not affect Type I IFN levels, but loss of
liver macrophages in Irgm1-/- mice resulted in reduced Type I IFN levels in the serum. These
tissue-resident macrophages, also called Kupffer cells, are important for clearance of erythroid
nuclei, senescent erythrocytes, and apoptotic cells and other debris (Davies et al., 2013). In
addition, their localization within the hepatic sinusoid allows them to phagocytose pathogens
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entering from the portal or arterial circulation (Dixon et al., 2013). Recent studies have also
identified a contributing role for Kupffer cells in liver injury, such as during alcoholic liver
disease and metabolic syndrome (Dixon et al., 2013). Due to their sentinel location within the
circulatory system, these cells may encounter self or foreign triggers of Type I IFN signaling.
Loss of Irgm1 in Kupffer cells could thus result in aberrant function and enhanced Type I IFN
production.
The molecular mechanism by which Irgm1 negatively regulates Type I IFN production is
unclear. Based on its localization pattern at the ER, Golgi and mitochondrial membranes, Irgm1
could interact with MAVS or STING, adaptors downstream of pattern recognition receptors
(PRRs) that induce Type I IFN production (Martens et al., 2004; Zhao et al., 2010). STING is
thought to be located on the endoplasmic reticulum (ER), possibly at the interface between the
mitochondria and the ER (Ishikawa and Barber, 2008). MAVS, on the other hand, is localized to
the mitochondrial membrane (Seth et al., 2005). STING is downstream of a DNA-sensing
pathway, and MAVs is an adaptor for RIG-I-like receptor (RLR) signaling, both of which
stimulate Type I IFN expression (Belgnaoui et al., 2011; Tanaka and Chen, 2012).
Studies of human IRGM provide further evidence that Irgm1 and IRGM could play a role
in the negative regulation of Type I IFN production. For example, IRGM has been associated
with ATG5, which in turn has been shown to inhibit Type I IFN production by associating with
mitochondria and binding MAVS. Association of an ATG5-ATG12 complex with MAVs
inhibited Type I IFN production upon viral infection or double-stranded RNA stimulation of
mouse embryonic fibroblasts (MEFs) (Jounai et al., 2007). Whether the process of autophagy
was involved in this process was not definitively examined. IRGM could thus limit Type I IFN
production by promoting the association of ATG5 with MAVs. Similar functions have been
43	
  
	
  

shown for mitofusin 2 and Tu translation elongation factor, mitochondrial proteins that both
induce autophagy and inhibit Type I IFN production (Lei et al., 2012; Yasukawa et al., 2009).
The importance of IRGM in regulating antiviral defense is underscored by a study that
showed that IRGM is a common target of RNA viruses (Gregoire et al., 2011). Using yeast-2hybrid arrays and bioinformatics analysis, Gregoire et al found that IRGM could interact with
proteins from 5 different families of RNA viruses. They proposed that RNA viruses target IRGM
to manipulate the autophagy pathway and enhance viral replication in vitro. However, it was
unclear whether this mechanism was of importance in vivo. An alternative hypothesis would be
that viruses target IRGM (or Irgm1) as a viral evasion mechanism because of its role in
regulating the Type I IFN response. Interaction with IRGM could promote negative regulation of
Type I IFN signaling and thus inhibit the antiviral response. While it is not known if Irgm1 and
IRGM have similar functions, it would still be informative to investigate whether phenomena
observed in humans are also found in mice, and vice versa.
Finally, a single study in a Chinese population also linked IRGM variants to SLE (Zhou
et al., 2011). While this was a small study in a limited population, it would be revealing to see if
the results hold up in a larger cohort. Since an elevation in Type I IFN signatures is associated
with some forms of SLE, it would be wise to separate out the study population into Type I IFNassociated and unassociated. It is tempting to speculate that IRGM variants could also result in
increased Type I IFN production in humans.
Finally, we observed that antibiotic treatment of Irgm1-/- mice did not normalize the Type
I IFN levels. However, even a broad-spectrum antibiotic regimen does not completely eliminate
all bacteria, and of course there could still be commensal viruses that could drive Type I IFN
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production. It would be of interest to re-derive the Irgm1-/- mice into a germ-free facility, and
determine whether Type I IFNs levels are still increased in the absence of any microbiota.
Based on the published literature and our current results, I propose that Irgm1 is
important for the regulation of proteins at intracellular membranes. I speculate that Irgm1
regulates the ability of STING, MAVs, or downstream signaling components, to effectively
localize to or function at the endoplasmic reticulum and the mitochondrial membrane,
respectively. Thus, in the absence of Irgm1, these signaling pathways are increased and Type I
IFN production augmented. It is possible that the variants observed in human IRGM could also
influence Type I IFN levels and affect disease pathogenesis and/or progression in Crohn's
disease and tuberculosis.
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Figure 2.1. Irgm1-/- mice bred at near-Mendelian ratios, were slightly smaller than WT
littermates, and were susceptible to Toxoplasma gondii infection. A) Graph of the average
fraction ± standard deviation (SD) of Irgm1+/+, Irgm1+/- and Irgm1-/- mice for 36 litters (193 mice
total). B) Graph of the average weights ± SD of differently-aged male Irgm1-/- mice compared to
WT male littermates. N=4-15 per group per age. P<0.0001 by 2 way ANOVA. **p<0.01,
***p<0.001, ***p<0.0001 by Sidak's multiple comparisons test. C) Graph of the mean bone
volume fraction of femurs of Irgm1-/- mice (n=2) and WT mice (n=3) at 12 weeks of age, as
measured by microCT scanning of the long bones. D) Kaplan-Meier survival curve of Irgm1-/mice (n=4) and age-matched WT mice (n=4) after oral infection with 7 cysts of T. gondii
(Prugniaud strain). p<0.01 by log rank test.
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Table 2.1. Irgm1-/- mice did not differ in multiple microCT femur measurements compared
to WT mice. Table of multiple parameters measured by microCT of the femur in WT and Irgm1/-

mice. TV - total volume, BV - bone volume, Conn.Dens - connective density, SMI - structure

model index, Tb. N- trabecular number, Tb.Th - trabecular thickness, Tb.Sp. - trabecular
separation. WT n=3 mice, Irgm1-/- n=2 mice. P value shown is by Student's t test.
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Figure 2.2. Microarray analysis of intestinal epithelium in Irgm1-/- and WT mice.
Microarray analysis was performed on RNA isolated from small intestinal epithelium of Irgm1-/and WT mice by laser capture microdissection (n=2 mice each genotype). Functional gene
annotation analysis of these genes identified significant elevations in “Interferon-mediated
immunity” genes (Bonferroni value = 2.47 E-13).
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Figure 2.3. Irgm1-/- mice did not have elevated IFNγ in the serum or tissues. Graph of IFNγ
levels as measured by ELISA in 6-9 week-old Irgm1-/- and WT serum, spleen, lung, bone
marrow, small intestine and colon. The limit of detection by ELISA (0.7pg/mL) is indicated by
the dotted line. N=2-4 mice per genotype for tissue homogenates; n=6 mice per genotype for
serum samples. No significant differences were observed between WT and Irgm1-/- values in
serum and all organs by Sidak's multiple comparisons test or by individual uncorrected Student's
t test.
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Annotation
2'-5' oligoadenylate synthetase 2 (Oas2)
immunoglobulin kappa chain complex (Igk) on chromosome
6
interferon-induced protein 44 (Ifi44)
similar to Interferon-activatable protein 203 (Ifi-203)
2'-5' oligoadenylate synthetase 1C (Oas1c)
interferon, alpha-inducible protein 27 like 2A
ubiquitin specific peptidase 18 (Usp18)
interferon-induced protein with tetratricopeptide repeats 2
(Ifit2)
myxovirus (influenza virus) resistance 2 (Mx2)
interferon-induced protein with tetratricopeptide repeats 3
(Ifit3)
interferon-induced protein with tetratricopeptide repeats 1
2'-5' oligoadenylate synthetase 3 (Oas3)
receptor transporter protein 4 (Rtp4)
immunoresponsive gene 1

Fold change
Gene Symbol (Irgm1-/-/WT)
Oas2
11.8
Rprl1
Ifi44
LOC623121
Oas1c
Ifi27l2a
Usp18

10.3
5.0
4.6
4.5
4.1
3.8

Ifit2
Mx2

3.4
3.4

Ifit3
Ifit1
Oas3
Rtp4
Irg1

3.2
3.1
3.1
3.0
2.9

Table 2.2. Interferon-stimulated genes are enriched in Irgm1-/- intestinal epithelium
compared to WT. Microarray data (see Figure 2) was manually inspected for genes expressed
downstream of Type I IFN signaling (ISGs). The top 14 ISGs enriched in Irgm1-/- intestinal
epithelium compared to WT intestinal epithelium are shown.
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Figure 2.4. Irgm1-/- mice had persistent, elevated circulating Type I IFNs.
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Figure 2.4. Irgm1-/- mice had persistent, elevated circulating Type I IFNs. A) Graph of
antiviral activity measured in serum using a bioassay system (described in Fig. 5). Mean values ±
SEM are plotted relative to WT. WT n=28 mice, Irgm1-/- n=33 mice from 9 independent
experiments. B) Bars show anti-viral activity of WT and Irgm1-/- serum after administration of
anti-Ifnar1 anti-pan-IFNα, and anti-IFNβ1 antibodies during the serum bioassay. WT n=4 mice,
Irgm1-/- n=6 mice. C) Graph of average ± SEM of antiviral activity relative to untreated WT
serum samples in the Type I IFN VSV-GFP bioassay. WT n=19 mice, Irgm1+/- n=7 mice. Means
are not significantly different by one-way ANOVA. D) Graph of the average MFI ± SEM of
VSV-GFP-infected L929 cells incubated with lung homogenate from WT and Irgm1-/- mice at 7
days of age. WT n=4 mice, Irgm1-/- n=3 mice. E) Graph of the average MFI ± SEM of VSVGFP-infected L929 cells incubated with serum from WT and Irgm1-/- mice at 17 weeks of age.
WT n=2 mice, Irgm1-/- n=4 mice. For B) to C), ***p<0.001; ****p<0.0001 by Sidak's multiple
comparisons test.
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Figure 2.5. Description of Type I IFN bioassay and validation of antibody specificity.
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Figure 2.5. Description of Type I IFN bioassay and validation of antibody specificity. A)
Schematic of Type I IFN bioassay (Newby et al., 2007). L929 cells were incubated with serum
or lung homogenate samples overnight, then infected with VSV-GFP for 10h. Levels of viral
infection were measured as median fluorescence intensity (MFI) of L929 cells via flow
cytometry. Antiviral activity relative to WT was calculated based on standard curves generated
using recombinant IFNαA for each experiment. The addition of neutralizing antibodies during
the incubation step allowed for determination of the source of antiviral activity. B) Graph
showing the specificity of neutralizing antibodies. Plot shows the MFI of VSV-GFP-infected
L929 cells incubated with 5 units/mL of recombinant murine IFNαA, 0.1 units/mL of
recombinant murine IFNβ, or no type I IFNs added. Anti-Ifnar (black bar), anti-pan-IFNα (gray
bar), and anti-IFNβ1 (gray striped bar) antibodies were administered. After VSV-GFP infection,
levels of viral infection (MFI) were measured by flow cytometry. ND: not done.
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Figure 2.6. Elevated Type I IFNs in Irgm1-/- mice were functional and protected against
influenza infection. A) Survival curve of 8-10 week-old male Irgm1-/- and WT mice upon
infection with 5000 pfu of influenza A/33/WSN. n=9 mice per genotype compiled from 3
experiments. p < 0.05 by Kaplan-Meier analysis (log-rank test). Type I IFNs and Ifnar have been
shown to be essential for host defense against influenza infection (Arimori et al., 2013; Koerner
et al., 2007). Ifnar-/- mice succumb to flu infection within days, and we would expect that Irgm1/-

Ifnar-/- mice would have similar susceptibility. B) Graph of influenza viral titers from whole

lung homogenate of WT (n=12 mice) and Irgm1-/- (n=9 mice) mice 6 days after infection with
5000pfu influenza A/WSN/33 virus. Viral titers were measured by plaque assay. C) to D) Graphs
of mean fold change ± SEM in B) Oas2 and C) Mx2 mRNA in Irgm1-/- tissues compared to WT
tissues. N=2-9 mice per genotype per organ. *p<0.05; ** p < 0.01, ****p<0.0001 by Student’s t
test.
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Figure 2.7. Irgm1-/- mice had Type I IFN-dependent cellular aggregates in the lung. A)
Representative images of lung cross sections in WT and Irgm1-/- mice. Length of red bar in
larger picture is 500µm; inset (red box) bar is 200µm. Graphs of B) the presence of lymphoid
tissue aggregates and C) the average ratio ± SD of lymphoid tissue aggregate to lung
parenchyma area was measured in Irgm1-/- (n=4), WT (n=4), Ifnar-/- (n=4), and Irgm1-/-Ifnar-/(n=5) mice using ImageJ software. *p<0.05 by Student's t test.
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Figure 2.8. Lung aggregates in Irgm1-/- mice were composed of a mixed lymphocyte and
myeloid population.
Figure 2.8. Lung aggregates in Irgm1-/- mice were composed of a mixed lymphocyte and
myeloid population. Representative immunofluorescence images of lung aggregates in Irgm1-/mice. A) CD45 – green. B) B220 – green, CD19 – pink. C) CD3 – purple, B220- green. D)
CD11c – yellow, CD19 – purple. E) B220 – pink, Gr1 – green. F) B220 – green, Siglec H – pink.
G) CD11b – green. All images at 200X.
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Figure 2.9. Antiviral activity was present in the lung and plasma fraction of the blood of
Irgm1-/- mice. Graphs of the average median fluorescent intensity (MFI) relative to WT MFI ±
SEM of VSV-GFP-infected L929 cells incubated with A) spleen, B) colon, C) bone marrow or
D-E) lung homogenate, or E) blood fractions. A) WT n=4 mice, Irgm1-/- n=8 mice. B) WT n=6
mice, Irgm1-/- n=10 mice. C) WT n=12 mice, Irgm1-/- n=18 mice. D-E) WT n=23 mice, Irgm1-/n=27 mice. F) WT n=2 mice, Irgm1-/- n=5 mice. *** p<0.001, ****p<0.0001 by Student's t test,
or by Tukey's multiple comparisons test (E only).
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Figure 2.10. No significant differences were observed in IFNα and IFNβ1 mRNA between
Irgm1-/- and WT organs. Graphs of A) IFNβ1 and B) pan-IFNα average mRNA expression
relative to WT in lung, small intestine (SI), colon, spleen (Spl), and bone marrow (BM)
homogenates in WT and Irgm1-/- (KO) mice. Ns as listed.
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Figure 2.11. Irgm1-/- and WT bone marrow-derived dendritic cells (BMDCs) had similar
sensitivity to polyI:C stimuli. Graph of A) pan-IFNα, B) IFNβ and C) IFNα4 average mRNA
expression ± SEM in BMDCs after 24hr stimulation with increasing amounts of polyI:C. WT
n=2 mice, Irgm1-/- n=2 mice with 2 technical replicates per sample.
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Figure 2.12. Irgm1-/- and WT bone marrow-derived dendritic cells had similar production
of Type I IFNs in response to polyI:C. Graphs of the average Type I IFN activity ± SEM of A)
BMDC supernatant and B) cell lysate 24hrs after administration of increasing polyI:C doses.
Type I IFN activity is shown as percentage of maximum MFI as measured by bioassay. N=2-8
mice per genotype per dose. Data is compiled from 3 independent experiments.
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Figure 2.13. WT and Irgm1-deficient intestinal epithelial cells had similar Type I IFN
production upon polyI:C treatment. Graphs of mRNA expression of A) pan IFNα, and B)
IFNβ1 after increasing doses of polyIC were added to primary intestinal epithelial cells from WT
and Irgm1-/- mice for 6 hours.
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Figure 2.14. WT and Irgm-deficient bone marrow cells had similar levels of Ifnar cell
surface expression. Representative flow cytometry histograms of A) WT, B) Irgm1-/- , and C)
Irgm1-/- Ifnar-/- whole bone marrow. D) Graph of the average MFI ± SEM of Ifnar expression in
WT, Irgm1-/-, and Irgm1-/- Ifnar-/- bone marrow using unstained cells, cells stained with isotype
control, and cells stained with an anti-Ifnar antibody. N = 2 mice per genotype.
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Figure 2.15. Irgm1 is expressed in T cells and monocytes. Immgen.org Gene Skyline display
for murine gene Irgm1.
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Figure 2.16. T and B cells were not required for elevated Type I IFN production in Irgm1-/mice. A graph of average antiviral activity in serum is shown as diminished average median
VSV-GFP expression ± SEM. Specificity for Type I IFN is shown in black bars by the addition
of anti-Ifnar antibody (Ab). WT n=2 mice, Irgm1-/- n=2 mice, Irgm1+/-Rag1-/- n=3 mice, Irgm1-/Rag1-/- n=3 mice.
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Figure 2.17. Liver macrophages played an important role in Type I IFN production in
Irgm1-/- mice.
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Figure 2.17. Liver macrophages played an important role in Type I IFN production in
Irgm1-/- mice. For A-B), mice were injected i.v. with 250µL of liposomes on d0, d3, and
sacrificed on d6. WT control n=2 mouse, WT clodronate n=2 mice, Irgm1-/- control n=2 mice,
Irgm1-/- clodronate n=3 mice. A) Graph of antiviral activity relative to WT control ± SEM of
serum from WT and Irgm1-/- mice injected with control and clodronate liposomes. Different
letters indicate significantly different means by Tukey's multiple comparisons test. B) Graph of
average MFI ± SEM of VSV-GFP-infected cells incubated with serum showing specificity for
Type I IFN by the addition of anti-Ifnar antibody (Ab) (black bars). *p<0.05; ** p<0.01 by
Tukey's multiple comparisons test. C) Graph of the average anti-viral activity ± SEM of serum
from Irgm1-/- mice injected with control (n=7 mice) and clodronate (n=8 mice) liposomes. Data
compiled from 2 independent experiments. **p<0.01 by Student's t test. D) Graph of the average
number of liver macrophages counted per 200X high power field (hpf) after staining frozen liver
sections with F4/80. 3 hpf were counted/mouse.
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Figure 2.18. Antibiotic treatment did not decrease Type I IFNs in Irgm1-deficient mice.
Graph of the average Type I IFN activity ± SD (shown as levels of VSV-GFP MFI) in serum as
measured by bioassay in mice after 2 weeks of antibiotic treatment (ampicillin, vancomycin,
neomycin, metronidazole) or mock treatment (Kool-Aid). Antibiotic treated mice n=4 each
genotype, vehicle-treated mice n=3 each genotype. * p<0.05, ** p<0.01, ns = not significant by
Tukey's multiple comparisons test.
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CHAPTER 3:
Type I Interferons link viral infection to enhanced epithelial turnover and repair
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INTRODUCTION
Epithelial cells create lining and duct structures that are associated with many organs in
the body (Blanpain et al., 2007). One major function of these structures is to provide a first-line
barrier of protection against the environment (Ashida et al., 2012; Diamond et al., 2000). A
central component of this protection is cellular turnover. This is a highly regulated process of
shedding and regeneration of differentiated cells while at the same time maintaining barrier
integrity. Loss of balance in this process (i.e. complete loss of regenerative capacity) results in
the eventual loss of barrier function. This concept is most obvious in the intestine, which
normally has a high epithelial turnover rate (Kuhnert et al., 2004; Lee et al., 2009). At
homeostasis, each distinct epithelial structure has a different rate of turnover, but the
determinants of these unique rates are poorly understood (Blanpain et al., 2007; Pellettieri and
Sanchez Alvarado, 2007).
Regardless of the intrinsic rate within a specific organ, turnover rates must be capable of
modulation in response to injury so that wound repair can efficiently occur. Damaged epithelial
cells must be shed and rapidly replaced with new cells generated by self-renewing stem cells
(Blanpain et al., 2007). In more severe injuries, stem cells themselves must also be replaced and
reorganized (Ito et al., 2007; Miyoshi et al., 2012). Examples of damage that can alter turnover
rates of the remaining stem cells include irradiation, malnutrition, and bacterial and parasitic
infection (Cliffe et al., 2005; Creamer, 1967; Luperchio and Schauer, 2001; Rijke et al., 1975).
The microbiome of the host is a key component of the environment that is involved in
homeostasis and injury response (Lai et al., 2009; Packey and Ciorba, 2010; Pfefferle and Renz,
2014; Scales and Huffnagle, 2013). The virome is a relatively unexplored component of the
microbiome and is the complex collection of chronic viruses within a given host (Virgin, 2014;
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Virgin et al., 2009). The role of these chronic viral infections in epithelial cellular turnover has
not been previously addressed.
Type I interferons (IFNs) are a candidate for mediating systemic alterations in response
to viruses. Type I IFNs are a family of innate immune cytokines that are produced as a result of
viral and other types of infection (Durbin et al., 2000; Muller et al., 1994) . They include
multiple IFNαs, IFNβ, and other subtypes (Hardy et al., 2004; Pestka et al., 2004). Once
expressed and secreted from the cell, Type I IFNs all bind to a common Type I IFN receptor,
IFNAR, which is expressed on most cell types (de Weerd et al., 2007). Despite sharing a single
receptor, Type I IFNs can have different cellular effects depending on the IFN subtype (α1 vs β,
etc.), the cell type, and the context (i.e. additional cytokine signals) (de Weerd and Nguyen,
2012; Ivashkiv and Donlin, 2014; Thomas et al., 2011). IFNAR lacks intrinsic kinase activity,
and is constitutively associated with the Janus kinases (JAKs) (Platanias, 2005). Upon ligand
binding, the JAKs phosphorylate the receptor and the signaling transducers and activators of
transcription (STATs) molecules (de Weerd et al., 2007). Upon phosphorylation, STATs form
complexes that translocate to the nucleus to induce the expression of hundreds of interferon
stimulated genes (ISGs).
It has been challenging to decipher the effects of Type I IFNs and downstream ISGs on
certain host physiologic processes such as epithelial turnover due to their critical and direct role
in anti-viral defense. However, ISGs can be involved in a plethora of additional cellular
processes. These include apoptosis, transcriptional activation and repression, modulation of
immune cells and cytokine expression, protein degradation, and post-transcriptional regulation of
gene expression (de Veer et al., 2001). The diversity of ISGs allows for pleiotropic responses and
the fine-tuning of host reactions to infection. Nevertheless, the functions of many ISGs are yet to
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be discovered, as it is difficult to use viral infection models to clarify the consequences of Type I
IFNs and ISGs on host physiology. To definitively show that Type I IFNs mediate an effect, loss
of function studies are required, but deficiency of Type I IFNs during a viral infection typically
results in unhindered viral replication, alterations in the immune response, and significant
morbidity and mortality. For example, loss of Type I IFN signaling during infection with murine
homologues of ubiquitous chronic viruses such as herpesvirus and cytomegalovirus results in
increased viral titers and mortality (Barton et al., 2005; Chong et al., 1983; Dutia et al., 1999;
Grundy et al., 1982). Here, we use an in vivo model, the Irgm1-/- mouse, that we found has
persistently elevated Type I IFNs in the absence of pathogenic viral infection and thus allowed
us to study the impact of Type I IFNs on host physiology. We showed that chronic viral infection
promoted epithelial turnover in multiple organs and was associated with enhanced injury repair.
We then demonstrated that Type I IFNs signaling through macrophages promoted epithelial
proliferation via novel functions of the ISGs, Apolipoprotein L9a and b.
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MATERIALS AND METHODS
Mice
All experimental procedures were performed under approval by Washington University's Animal
Studies Committee. Irgm1-/- mice were provided by Dr. Gregory A. Taylor (Duke University,
Durham, NC; (Collazo et al., 2001)). Ifnar-/- mice are deficient in Ifnar1 (Muller et al., 1994) and
Ifnarf/f mice have a floxed allele of Ifnar1 (Kamphuis et al., 2006). These mice were provided by
Dr. Robert D. Schreiber and Dr. Herbert W. Virgin (Washington University in St. Louis, St.
Louis, MO; (Thackray et al., 2012)). Villin-Cre (Madison et al., 2002) and LysM-Cre (Clausen et
al., 1999) mice were obtained from Jackson labs. All mice were re-derived into our enhanced
barrier facility and were fully backcrossed to a C57BL/6 background. For experiments with
knockout mouse lines, heterozygote breeding pairs were used to obtain WT controls. For
experiments using lineage specific knockouts, heterozygous crosses were used to generate Crenegative controls. Cdc25A-CBRLuc reporter mice were generated on a B6(Cg)-Tyrc-2J/J (B6albino) background. Briefly, a targeting construct containing DNA encoding a fusion protein of
Cdc25A and click beetle red luciferase (CBRLuc) was knocked-in to the Cdc25A locus by
homologous recombination. Mice were backcrossed using speed congenics to create the Cdc25ACBRLuc congenic mouse line.

In vivo treatment of mice
For murine cytomegalovirus (MCMV) infection, 6-8 week-old male and female mice were
injected intraperitoneally (i.p.) with 5x104 plaque-forming units (pfu) MCMV Smith strain
(salivary gland-derived). Mice were sacrificed 7 days post-infection. For gammaherpesvirus 68
(MHV68) infection, 6-8 week-old male and female mice were injected i.p. with 1x106 pfu virus.
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Mice were sacrificed 7 days post-infection. Titer determinations for both MCMV and MHV68
were performed on NIH 3T12 fibroblasts with methylcellulose overlay as previously described
(Canny et al., 2014). The limit of detection of the MCMV plaque assays was 40PFU/organ,
while the limit of detection of the MHV68 assay was 100PFU/organ. For
polyinosinic:polycytidylic acid (polyI:C) experiments, 5mg/kg polyI:C (GE Healthcare Life
Sciences) diluted in sterile saline or saline alone was injected intraperitoneally (i.p.) once every
24h for 4 days. Mice were sacrificed on day 5. For neutrophil-depletion experiments,
500µg/mouse of monoclonal anti-Ly6G antibody (BioXCell) or rat IgG2a isotype control
(BioXCell) diluted in 250µL sterile saline was injected i.p. one day prior and 2 days following
the onset of polyI:C injections.

Enzyme-linked immunosorbent assay
The mouse angiogenesis ELISA strip for profiling 8 cytokines (Signosis) was used to measure
levels of pro-proliferative cytokines in serum diluted at either 1:10 or 1:5 in assay diluent.

Type I IFN bioassay
Type I IFN bioassay was performed as previously described in Chapter 2 Materials and Methods
(Newby et al., 2007).

RNA isolation and Quantitative real-time PCR
RNA isolation and qPCR was performed as described in Chapter 2 Materials and Methods.
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Tissue histology
Tissue sections were harvested and fixed in Bouin’s fixative, methacarn, or 10% neutral-buffered
formalin for 3h at room temperature (RT), 1-2h at RT, or overnight at 4°C, respectively. Sections
were then washed in 70% ethanol and stored at 4°C until blocking. Organs were blocked in 2%
agar, paraffin-embedded, and 5µm sections were cut. Epithelial mitotic figures were quantified
from H+E-stained sections of Bouin's fixed small intestines. Crypt depth was measured from the
same sections by ImageJ software. All slides were blinded prior to quantification.

Ki67and β-catenin staining
Ki-67 immunohistochemistry staining was performed on formalin-fixed sections by first
performing antigen-retrieval with heated 10mM citrate buffer (pH 6.0). Antibody staining was
completed with rat monoclonal anti-Ki-67 primary antibody (clone TEC-3: DAKO) at a 1:100
dilution followed by a mouse-adsorbed rabbit anti-rat biotinylated secondary antibody (Vector
Laboratories) at a 1:200 dilution. Staining was visualized by Vectastain ELITE ABC kit (Vector
Laboratories) and DAB (3,3'-diaminobenzidine) peroxidase substrate (Vector Laboratories). The
number of Ki67 positive cells per high power field (hpf) at 400X was quantified. β-catenin
staining was performed on formalin-fixed sections without antigen retrieval. The primary
antibody used was a mouse monoclonal antibody (BD Transduction Laboratories C19220) at a
1:1000 dilution, and the secondary antibody was a biotinylated goat anti-mouse IgG diluted
1:200. DAB staining was visualized as described above for Ki67.
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Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
TUNEL staining was carried out on formalin-fixed, paraffin-embedded sections. Labeling was
done with terminal transferase (New England Biolabs M0315S) and DIG-dUTP (Roche
11093088910) for 2h at 37°C. Anti-DIG-AP FAb fragments were applied for 1h at RT. Alkalinephosphatase staining was then visualized with nitro blue tetrazolium chloride (NBT) (Roche
11383213001) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche 11383221001).

Thymidine analog experiments
BrDU/FrDU (5-Bromo-2'-deoxyuridine/5-Fluoro-2'-deoxyuridine; Sigma) was injected
intraperitoneally 1h before sacrifice. Goat anti-BrDU was used to label S phase cells. The
number of BrDU positive cells per 50 crypts was counted. IdU (Sigma I7125) and CldU (Sigma
C6891) were prepared in sterile saline at a concentration of 4mg/mL and 17mg/mL, respectively.
CldU was injected i.p. at 42.5mg/kg 36 h before sacrifice and IdU at 42.5mg/kg 24h before
sacrifice. Detection of CldU was performed with rat anti-BrdU (clone BU1/75: Accurate
Chemical and Scientific Corporation, #OBT0030) and Alexa 594-conjugated donkey anti-rat
antibody (Life Technologies). IdU was detected using mouse anti-BrdU (clone B44: BD
#347580) and Alexa 488-conjugated donkey anti-mouse antibody (Life Technologies). The
distance migrated in a 12h period was calculated by measuring the distance between the highest
positioned CldU-stained cell and the first IdU-stained cell (along the crypt-villus axis) using
ImageJ software.
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Intestinal spheroid epithelial culture
Colonic and small intestinal crypts were isolated from mice and cultured in a 3D-Matrigel as
described in Chapter 2 Materials and Methods.

EdU Click-iT cell cycle flow cytometry assay
For serum and recombinant interferon experiments, cells were incubated with 5% L-WRN
conditioned media at 37°C for 24h after passage, washed, and then treatment was added for an
additional 24h. 10µM EdU was administered at 22h post-treatment. 2h later, spheroids were
isolated out of 3D culture in PBS-EDTA. A single cell suspension was obtained by
trypsinization. The EdU Click-iT Flow Cytometry Assay kit (Invitrogen) was then used to
determine the percentage of S-phase cells according to the manufacturer's instructions. Flow
cytometry data was analyzed using FloJo software.

Microarray
RNA was extracted using an RNeasy kit (Qiagen) from small intestine tissue, submandibular
salivary gland tissue, and colonic macrophages. Colonic macrophages were isolated as
previously described (Malvin et al., 2012). RNA from colonic macrophages was amplified using
a complete whole transcriptome amplification kit (Sigma WTA2 kit). Microarray analysis was
performed on 4x44K mouse whole genome microarrays (Agilent) as previously described
(Cadwell et al., 2010). Hierarchical clustering and statistical analysis were performed using
Partek software.
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In situ hybridization
Probe synthesis and in situ hybridization was performed as previously described (Miyoshi et al.,
2012) with the exception that tissue was fixed in methacarn solution (60% MeOH, 30%
chloroform stabilized with ethanol, 10% acetic acid) followed by paraffin embedment. Antisense RNA probe was synthesized from an Apol9a cDNA clone (clone ID: 2649139, GE
Healthcare).

293FT supernatant harvest and transfer
293FT cells were plated in a 90mm dish with antibiotic-free media for 24h. Media was changed
and 10ug of Apol9a-Myc-DDK (Origene, Accession No. NM_001162883) plasmid transfected
with lipofectamine. The next day, cells were washed and media was changed to serum-free
primary epithelial cell culture media. Supernatant was harvested 24h later and spun down to
remove cells. Flag-tagged protein was then detected by immunoblotting (see below). For
supernatant transfer experiments, 293FT cells were plated as above and transfected with
untagged Apol9a (clone ID: 2649139, GE Healthcare). Cells were washed the next day and
media was changed to serum-free primary epithelial cell culture media. Supernatant was
harvested 24h later and concentrated 5X with Centriprep Centrifugal filter units (Millipore) that
enables concentration of proteins >10kDa. Supernatant was then diluted 1:1 with 50% L-WRN
conditioned media and incubated with primary intestinal epithelial cells for 24h before cells were
harvested for RNA and qRT-PCR analysis.
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Lentivirus expression in intestinal epithelial spheroid cultures
Apol9a (clone ID: 2649139, GE Healthcare), Rspo3 (Miyoshi et al., 2012), and puromycin
(negative control) cDNAs were individually cloned into C274-IRES-GFP lentivirus constructs.
Virus was generated in 293FT cells, and concentrated with PEG-it virus precipitation solution
(Miyoshi and Stappenbeck, 2013). Spheroid cells were trypsinized into single cell and multi-cell
clusters, suspended in media, and incubated with virus constructs for 6h at 37°C in the presence
of ROCK inhibitor (Y27632, R&D Systems). Cells were then plated in Matrigel and expanded as
described above.

Characterization of the proliferation reporter Cdc25A-CBRLuc
Mice were injected intraperitoneally with D-luciferin (Biosynth, 150 mg/kg body weight).
Within 30min of injection, mice were sacrificed and organs were rapidly isolated. Imaging was
performed using an IVIS Lumina at 37°C (Caliper) using the following acquisition parameters:
Exposure time-5min, Binning-8, no filter; f/stop, FOV-12.5cm. Grayscale photographs and color
luciferase images were superimposed and analyzed with Living Image software 3.2 (Caliper) and
Igor (Wavemetrics) image analysis software (Gross and Piwnica-Worms, 2005).

Bioluminescence imaging of whole organs and intestinal epithelial spheroids
Colonic crypts were isolated from knock-in mice that were homozygous (ALuc/ALuc) for the
Cdc25A-CBRLuc fusion protein and intestinal spheroids were cultured in conditioned media as
described above. For initial luminescence imaging, spheroids were trypsinized and seeded onto
96-well plates. After overnight culture, fresh media with 300µg/ml D-luciferin (Biosynth) was
added to each well, and 30 min later, cells were imaged at 37°C in an IVIS Lumina (Caliper)
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using the following acquisition parameters: Exposure time-3min, Binning-8, no filter; f/stop, FOV12.5cm. To measure photon flux, Regions of Interest (ROIs) of identical size were drawn over
every well (red square grids) and analyzed as photons emitted per second. Identical instrument,
field of view, f-stop, exposure and binning settings were used within an experiment. Color
luciferase images and grayscale photographs were superimposed and analyzed with Living
Image software 3.2 (Caliper) and Igor (Wavemetrics) image analysis software. For luminescence
experiments with lentivirus construct-expressing cells, spheroids were trypsinized and seeded
onto 96-well plates. Media containing 200µg/mL D-luciferin (Biosynth) was added to each well,
and 20-30min later, cells were imaged at 37◦C in an Envision Multilabel Plate reader (Perkin
Elmer) with a 1 second exposure per well. Luminescence was reported as relative light units.
Luminescence was measured every 4h for 24h and the fold change in luminescence relative to
luminescence measured at 4h was plotted. In MEK inhibitor experiments, different
concentrations of U0126 (Promega) in DMSO or DMSO alone was added once immediately
after seeding cells.

MTS assay of intestinal spheroids
To measure the number of viable cells, intestinal epithelial spheroids were plated as described
above and subjected to MTS assay (tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) and an electron
coupling reagent (phenazine methosulfate; PMS) as described by CellTiter 96® AQueous Assay
Kit (Promega). Metabolism of MTS to soluble formazan by living cells was measured by
absorbance at 490 nM using a luminometer (Multiskan). All graphs were plotted using
Kaleidagraph software (Synergy).
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Phospho-kinase dot blot array
A phospho-kinase array kit (R&D) was used according to the manufacturer's instructions.
Briefly, control, Rspo3- and Apol9a-expressing cells were plated in 50% conditioned media for
24h. Cells were harvested using Cell Recovery Solution (BD Biosciences) and lysed with
phospho-kinase array kit lysis buffer to obtain protein. Lysates were incubated overnight with the
phospho-kinase array membranes. Membranes were washed and incubated with a cocktail of
biotinylated detection antibodies. Streptavidin-HRP was added and signal detected by
chemiluminescence.

Immunoblotting
Intestinal spheroid cells were plated as described above for the phospho-kinase array. Cells were
harvested using Cell Recovery Solution (BD Biosciences), pelleted, and lysed in RIPA buffer
with protease inhibitors (Sigma) and phosphotase inhibitors (Nacalai USA). Samples were run
on Any-KD Mini-Protean gels (Bio-Rad) and transferred onto nitrocellulose membrane (BioRad). Membranes were blocked with Blocking One (Nacalai USA) and washed with TBS-T
buffer. Membranes were incubated with primary antibodies (anti-Phospho p44/42 MAPK
(Thr202/Tyr204) and anti-p44/42 MAPK; Cell Signaling) in 5% BSA in TBS-T buffer overnight
at 4°C. Membranes were then incubated with horseradish peroxidase (HRP) conjugated
secondary antibodies (Bio-Rad) for 1h at room temperature. Signal was detected using the
SuperSignal West Dura chemiluminescence kit (Thermo Fisher Scientific).
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Statistics
GraphPad Prism software (version 6) was used to perform all statistical analyses unless
otherwise specified.
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RESULTS
Chronic viral infection promoted turnover of multiple epithelial organs
We first investigated whether chronic viral infection can modulate epithelial turnover.
We infected C56BL/6 wild-type (WT) mice with murine cytomegalovirus (MCMV), a DNA
herpesvirus that provides an animal model for infection with human CMV, a highly prevalent
chronic virus (Brune et al., 2001; Virgin et al., 2009). Seven days after infection, we observed
increased epithelial cell proliferation (by Ki67 staining) and cell death (by TUNEL staining)
within organs that normally show low levels of epithelial turnover (i.e. kidney, liver, salivary
gland, and pancreas; Figure 3.1A-C) (Pellettieri and Sanchez Alvarado, 2007). The continued
local presence of infectious virus was not required for increased turnover, as only the salivary
gland had detectable titers at this time (Figure 3.2A). A homologue of chronic human
herpesvirus, murine gammaherpesvirus 68 (MHV68; (Virgin et al., 2009)), also promoted
epithelial proliferation 16 days post-infection in the absence of detectable titers in target tissues
(Figure 3.3A). At this time point, MHV68 is entering its chronic latent phase (Tibbetts et al.,
2003). However, in the small intestine, an organ with high constitutive epithelial turnover, we
found that while MCMV stimulated an increase in proliferation (Figure 3.1D-E), infection with
MHV68 or a persistent strain of enteric murine norovirus (Nice et al., 2013) did not (Figure
3.3B-E). These results suggested that certain chronic viral infections can promote epithelial
turnover in multiple organs.

Mice deficient in Irgm1 provided a useful model to study the effects of chronic elevated Type I
IFNs

85	
  
	
  

We hypothesized that Type I IFNs induced by viral infection stimulated epithelial
turnover. However, we could not test this hypothesis in mice completely lacking Type I
interferon responses because these cytokines are required for survival after infection with
MCMV and MHV68 (Barton et al., 2005; Chong et al., 1983; Dutia et al., 1999; Grundy et al.,
1982). Therefore, we used a mouse model that we discovered has chronic elevated Type I IFN
levels in the absence of infection, the Irgm1-/- mouse. Irgm1 is a p47 GTPase initially studied for
its role in host defense against intracellular protozoans and bacteria and in autophagy (Collazo et
al., 2001; Feng et al., 2004; Liu et al., 2013; Santiago et al., 2005). The systemic elevation of
Type I IFNs in Irgm1-/- mice is described in detail in Chapter 2 of this thesis, and provided us
with a useful model to study the role of these cytokines on host physiology.

Type I IFNs promoted epithelial proliferation and turnover
To determine if Type I IFNs increased epithelial turnover, we compared WT, Irgm1-/-,
and Irgm1-/-Ifnar-/- mice that lack responsiveness to Type I IFNs but still have elevated Type I
IFN serum levels (Figure 3.4). We found increased epithelial proliferation and cell death in the
kidney, pancreas, liver, and salivary gland of Irgm1-/- mice but not Irgm1-/-Ifnar-/- mice compared
to WT mice (Figures 3.5A-B and 3.6A). The effects of Type I IFNs were not global, as
proliferation levels in skeletal muscle, lung alveolar cells, and thyroid gland epithelial cells in
Irgm1-/- mice were similar to controls (Figure 3.6B).
We further examined the effect of Type I IFNs on proliferation in the intestine, where
proliferation, cell death, and cell migration occur in defined areas (Creamer, 1967; Potten, 1998).
Irgm1-/- but not Irgm1-/-Ifnar-/- intestines showed increased epithelial proliferation compared to
controls, as assessed by crypt height, number of mitotic figures per crypt, and incorporation of
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the thymidine analog BrdU (Figure 3.5C-F). Increased proliferation was observed throughout
Irgm1-/- small intestinal crypts, including regions enriched for stem cells (crypt base) and regions
enriched for transit-amplifying cells (upper crypt) (Figure 3.6D). Turnover in the small intestine
takes place, in part, via cell migration from the base of crypts that culminates with the eventual
shedding of cells at the tips of villi (Creamer, 1967). Using a double thymidine analog method
(Mahoney et al., 2008), we found that the distance migrated by epithelial cells was greater in
Irgm1-/- mice than in either WT or Irgm1-/-Ifnar-/- mice (Figures 3.5E and 3.6G). Notably, there
was no excess cell death in crypts or villi of Irgm1-/- mice (Figure 3.7A). Furthermore,
recombinant murine IFNαA did not induce cell death in epithelial spheroid cultures (Miyoshi et
al., 2012; Miyoshi and Stappenbeck, 2013) derived from WT, Ifnar-/- and Irgm1-/- mice, despite
the capacity of WT and Irgm1-/- cells to respond to type I IFNs by increasing ISG expression
(Figure 3.7B-C). These findings suggest that enhanced proliferation, and not apoptosis, is the
primary driver of Type I IFN stimulated epithelial turnover in Irgm1-/- mice.

Elevated Type I IFNs in Irgm1-/- mice enhanced wound healing
To determine whether Type I IFN-driven epithelial turnover had physiologic importance,
we evaluated wound repair. We first administered diclofenac sodium salt, a non-steroidal antiinflammatory drug (NSAID), which can induce small intestinal ulcerations within 24 hours after
a single i.p. dose of 60mg/kg (Fujimori et al., 2010; Ramirez-Alcantara et al., 2009). While
ulcers were formed in all mice after 18 hours, Irgm1-/- mice had fewer detectable intestinal ulcers
compared to WT and Irgm1-/-Ifnar-/- mice at day 2 and day 4 after injection (Figures 3.8A-B and
3.9). This result indicated that Irgm1-/- mice healed ulcerations more rapidly than controls. We
confirmed this finding using a colonic biopsy injury model (Seno et al., 2009). In this model,
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wound-associated epithelial (WAE) cells migrate over the wound bed surface to cover the injury,
and decreased epithelial cell proliferation in wound-adjacent crypts is associated with slowed and
incomplete wound healing (Seno et al., 2009). We observed a greater distance covered by WAE
cells at day 4 post-injury in wounds of Irgm1-/- mice compared to wounds in WT and Irgm1-/Ifnar-/- mice (Figure 3.8C-D). In addition, we examined wound healing responses in the context
of MCMV infection. We injected diclofenac 4 days after systemic MCMV infection, and
enumerated ulcers 18hours and 4 days afterward. Interestingly, MCMV-infected mice had fewer
ulcers than mock-infected mice even at 18hours, suggesting that viral infection may have
hindered ulcer formation (Figure 3.8E-F). In addition, many ulcers in MCMV-infected animals
had an abnormal appearance, with what appeared to be slight villus ablation without the
penetrating ulcers and wound debris seen in mock-infected and WT mice at this time point
(Figures 3.8F and 3.9). Taken together, these findings suggest that elevated epithelial
proliferation in response to Type I IFNs and enhanced healing after epithelial damage, and that
the presence of viral infection altered NSAID-induced wound formation.

Type I IFNs signaled through macrophages to promote epithelial proliferation
We then tested whether Type I IFNs act directly on the epithelium to promote
proliferation by crossing Irgm1-/- mice with mice lacking Ifnar solely in the intestinal epithelium
(Irgm1-/-Ifnarf/f-Villin-Cre; Irgm1-/- IfnarVC mice (el Marjou et al., 2004)). Importantly, Irgm1-/IfnarVC mice had elevated levels of serum Type I IFNs, and increased intestinal epithelial
proliferation comparable to Irgm1-/- mice (Figures 3.4 and 3.10A-B). This finding suggested
that non-epithelial cell type(s) must be responding to Type I IFNs to stimulate epithelial cell
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proliferation. We verified this finding in vitro: addition of IFNα did not affect proliferation of
primary intestinal epithelial cells in the absence of other cell types (Figure 3.11).
Next, to identify the cell type required for epithelial hyperproliferation to type I IFN, we
assayed mice deficient in different cellular compartments after treatment with polyI:C, a
synthetic dsRNA. Daily low dose polyI:C injection for 4 days induced elevated systemic Type I
IFN and increased intestinal epithelial proliferation in WT but not Ifnar-/- mice (Figures 3.10C
and 3.12A-B). PolyI:C treatment of IfnarVC mice also showed augmented intestinal epithelial
turnover (Figure 3.12D-E). However, polyI:C treatment of mice lacking Ifnar on macrophages
and granulocytes (Ifnarf/f-LysM-Cre; IfnarLysM mice (Prinz et al., 2008)) did not induce
epithelial cell proliferation to the same extent as in control mice (Figure 3.10D), even though
Type I IFN levels were induced at similar levels in both IfnarLysM and control mice (Figure
3.13A). Endogenous lysozyme M is highly expressed on both neutrophils and macrophages
(Cross et al., 1988; Faust et al., 2000). However, neutrophil depletion did not diminish epithelial
hyperproliferation induced by polyI:C injection, indicating that macrophages mediate this effect
(Figures 3.10E and 3.13B-C).

The ISG Apolipoprotein L9 was a candidate factor to mediate proliferation in Irgm1-/- mice
We next determined the factors downstream of IFN signaling that can mediate increased
epithelial turnover. We assayed serum from Irgm1-/-, WT, polyI:C-treated and saline-treated
mice, but found no elevations in established pro-proliferative cytokines and growth factors
TNFα, IL-6, IGF, leptin, EGF, VEGF, and FGFβ (Figure 3.14A-B). We therefore performed
microarray expression analysis of whole genome RNA of salivary gland, small intestine and
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isolated colonic macrophages from Irgm1-/- and WT mice (Figure 3.15A). Apol9a and Apol9b,
highly homologous apolipoproteins (98% by nBLAST analysis), were two of the few factors
with enhanced gene expression in Irgm1-/- mice that were also potentially secreted (Figure 3.15B
and Table 3.1). These apolipoproteins are ISGs (Rusinova et al., 2013), however their function
is unknown. We verified enriched gene expression of Apol9a/b using qRT-PCR in small intestine
and salivary gland whole tissue, and isolated colonic macrophages of Irgm1-/- mice (Figure
3.16A). Apol9a/b gene expression was also elevated in MCMV-infected tissues with epithelial
hyperproliferation compared to mock-infected animals (Figure 3.16B).
We further examined localization of Apol9a expression by in situ hybridization.
Interestingly, Apol9a was expressed in discrete foci within the salivary gland and small intestine
in Irgm1-/- mice (Figure 3.16C-D). Apol9a was not only expressed in the stroma, where
macrophages reside, but also in epithelial cells themselves (Figure 3.16C-D, insets). Based on
this pattern, we hypothesized that Apol9a/b may be secreted from macrophages in response to
Type I IFN and stimulate its own expression in surrounding cells. Alternatively, other ISGs from
macrophages could stimulate Apol9a/b expression in the epithelial cells. Indeed, we found that
Apol9a/b expression was induced by IFNαA in WT but not Ifnar-/- macrophages (Figure 3.17A).
We then transfected 293FT cells with Flag-tagged Apol9a. We could detect Flag-tagged Apol9a
protein within the supernatant, suggesting that Apol9a can be secreted (Figure 3.17B). In
addition, Apol9a expression could be found in the intestinal epithelium of Irgm1-/- IfnarVCmice, which supported the idea that Apol9a/b expression in epithelium can be indirectly
stimulated (Figure 3.17C).

Apolipoprotein L9 promoted epithelial proliferation through ERK activation
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Notably, the pattern of Apol9a gene expression within the salivary gland was associated
with areas of high epithelial proliferation (Figure 3.18). To determine whether Apol9a could
promote proliferation, we quantified proliferation of Apol9a-expressing intestinal epithelial cells
using a novel bioluminescence-based assay. This method utilized knock-in mice expressing a
fusion protein between Cdc25A and click beetle red luciferase (CBRLuc) in the endogenous
Cdc25a locus (Figure 3.19A-B). Cdc25A is a cell cycle phosphatase with peak protein levels
during mitosis (Boutros et al., 2006) (Honaker and Piwnica-Worms, 2010). Luminescence from
Cdc25A-CBRLuc-expressing cells upon addition of D-luciferin substrate thus provided a direct
readout of mitotic activity and proliferation. Luminescence imaging of Cdc25A-CBRLuc colonic
epithelial spheroid cultures revealed an increase in luminescence over a 48h culture period
(Figures 3.19C-D) that correlated with the number of viable cells (Figure 3.19E).
We assessed luminescence levels of Cdc25A-CBRLuc intestinal epithelial cells
expressing either Apol9a, a positive control R-spondin3 (Rspo3), or a negative control construct
for 24 hours (Figures 3.20A). R-spondins enhance Wnt signaling to promote cell proliferation
and survival of tissue stem cells, and exogenous R-spondin can increase intestinal crypt
proliferation (Haegebarth and Clevers, 2009; Kim et al., 2005). Both R-spondin3 and Wnt3a are
required in the normal growth media for primary intestinal epithelial spheroids (Miyoshi et al.,
2012; Miyoshi and Stappenbeck, 2013). Under these conditions, small intestinal epithelial cells
expressing Apol9a and the positive control Rspo3 showed greater proliferation compared to
control cells (Figure 3.19F). To determine whether Apol9a could substitute for Rspo3 to
enhance Wnt signaling, we grew cells in media with only Wnt3a present. In these conditions,
only epithelial cells expressing Rspo3 were able to proliferate, suggesting that Apol9a functions
through a different pathway (Figure 3.19G). Indeed, no significant enhancement of Wnt
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signaling was observed in vivo in Irgm1-/- mice as assessed by two downstream indicators of Wnt
activation, β-catenin nuclear localization or Axin2 expression (Figure 3.20B-C). Similar results
on proliferation were obtained in WT cells expressing Apol9a and Rspo3 using an EdU
incorporation assay (Figure 3.20D). These results suggested that Apol9a expression within
epithelial cells is able to stimulate epithelial proliferation.
Next, to discover potential pathways downstream of Apol9a expression, we analyzed cell
lysates of control, Rspo3, and Apol9a-expressing intestinal epithelial cells using a phosphokinase dot blot array. Out of 45 different phosphorylated kinase targets, Apol9a-expressing
epithelial cells showed elevations in phospho-ERK1/2 compared to control cells (Figure 3.21A).
We verified this finding by Western blot (Figure 3.19H). ERK kinases are the downstream
signaling component of the mitogen-activated protein kinase (MAPK) pathway, and have been
implicated in promoting cell cycle progression and proliferation (Rubinfeld and Seger, 2005;
Shaul and Seger, 2007). Addition of the MEK inhibitor U0126 inhibited ERK1/2
phosphorylation and reduced proliferation of Apol9a-expressing intestinal epithelial cells, as
well as control cells, in a dose-dependent manner (Figures 3.19I and 3.20G-H). These findings
implicated activation of the ERK pathway, which is important for epithelial cell proliferation,
downstream of Apol9a expression.

Macrophages expressing Apol9a were able to promote epithelial proliferation in trans
Finally, we investigated the role of Type I IFN signaling in macrophages on Apol9amediated epithelial proliferation. Based on the localization of Apol9a on macrophages by in situ
hybridization (Figures 3.16C-D), we determined whether Type I IFN signaling could induce
Apol9a/b in macrophages and stimulate proliferation in trans. We expressed Apol9a or a control
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construct in WT bone marrow-derived macrophages and co-cultured these cells with Cdc25ACBRLuc intestinal epithelial cells. Macrophages expressing Apol9a enhanced proliferation of
epithelial cells greater than control macrophages or epithelial cultures alone (Figure 3.22). These
results suggested that macrophages promoted epithelial proliferation in trans via Apol9a
expression.
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DISCUSSION
Taken together, these findings uncover a novel pathway linking viral infection with
enhanced epithelial turnover via Type I IFNs. Specifically, we showed that elevated Type I IFNs
can signal through macrophages to enhance epithelial proliferation and injury repair. We
demonstrated that the highly related IFN-stimulated genes Apol9a and b promote epithelial
proliferation. These results redefine the current view of Type I IFN effects on proliferation in
vivo and enhance our understanding of conditions with elevations in these cytokines, such as
viral infection and autoimmunity.
The indirect effect on epithelial proliferation driven by viral infection has not been
previously described. The viruses used here that stimulated epithelial proliferation are murine
homologues of highly prevalent human chronic viruses, CMV and herpesvirus, both well-known
systemic DNA viruses (Virgin et al., 2009). In contrast, murine norovirus, an RNA virus, did not
stimulate proliferation in the intestine, where it is tropic (Nice et al., 2013). These results suggest
that not all viruses can stimulate enhanced epithelial proliferation, perhaps due to differences in
tissue tropism, viral pathogenesis and/or virus-encoded pathogen associated molecular patterns
(PAMPs). In humans, host factors may also play a role in the extent of induced proliferation, as
genetic differences can affect immune responses to pathogens, including the Type I IFN response
(Lee et al., 2014). Since chronic viral infection clearly has a systemic effect on host physiology,
and all individuals possess a collection of persistent viruses as their virome, the use of mouse
models of chronic viral infections may uncover new biology.
Type I IFNs have been generally considered to be pro-apoptotic and anti-proliferative,
but the vast majority of these studies were performed with direct administration of these
cytokines onto cells in vitro (Chawla-Sarkar et al., 2003; Maher et al., 2007; Tanaka et al., 1998).
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Our results show that the effects of Type I IFNs in vivo are more complex, as Type I IFNs do not
directly stimulate either apoptosis or proliferation of primary intestinal epithelial cells in vitro.
These findings are in stark contrast with recent studies showing that Type II IFN, IFNγ, directly
mediates intestinal epithelial cell death in vitro and in vivo (Farin et al., 2014; Moon et al., 2013).
We found that the effects of Type I IFN on epithelial proliferation are indirect through an
additional cell type that includes macrophages. We propose that macrophages can act as a relay.
Because of their widespread distribution, these cells are poised to synthesize information from
multiple local and remote sources and then in turn instruct proximal epithelial cells. The use of
an integrative relay enables the separation of signal from noise and allows for the amplification
of additive weak signals. The pattern of foci of Apol9a expression in stromal and epithelial cells
observed in the salivary gland and small intestine supports the concept of a central cell that
spreads and amplifies signals to neighboring cells. This myeloid-epithelial circuit could be used
by other cytokine signaling systems to modulate diverse epithelial functions. Our work extends a
proposed role for macrophages in epithelial maintenance and repair by implicating Type I IFNs
in this pathway (Farache et al., 2013). The host immune system may thus prime the epithelium
for renewal and healing in response to additional damage.
We propose that Apolipoprotein L9 is one of the mediators of this Type I IFN response
directed towards epithelial progenitors. Relatively little is known about the Apolipoprotein L
(ApoL) family. In humans, there are 6 known ApoLs, 5 of which are thought to be interferonstimulated (Rusinova et al., 2013; Smith and Malik, 2009). In mice, there are as many as 14
apolipoprotein L members (Vanhollebeke and Pays, 2006). In contrast to other apolipoprotein
families, only APOL1 has been implicated in lipid transport and metabolism to date (Albert et
al., 2005; Duchateau et al., 2000; Duchateau et al., 1997). APOL1 also has pore-forming
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trypanolytic activity against Trypanosoma brucei, and may be involved in the autophagy
pathway (Perez-Morga et al., 2005; Vanhamme et al., 2003; Wan et al., 2008). In addition,
APOL1 and APOL6 have been implicated in mediating cell death (Liu et al., 2005; Wan et al.,
2008), while APOL2 was shown to be protective against IFNγ-induced cytotoxicity (Liao et al.,
2011). Interestingly, increased expression of ApoLs has been observed in several cancers,
including cervical and breast cancer (Ahn et al., 2004; Jung et al., 2005). Apol9a and Apol9b
have the most protein homology with APOL3 (43% identity), but may share similar structural
domains with the rest of the ApoL family. Apol9b has been implicated in anti-viral protection in
L929 cells and primary neurons, but the extent and mechanism of such protection was unclear
(Kreit et al., 2014). In this report, we show that Apol9a can be secreted and promotes epithelial
proliferation. Since there are hundreds of ISGs that can be induced in a given cell type, it is
unlikely that Apol9a and b are the sole mediators of Type I IFN-dependent epithelial
proliferation. Other ISGs may have redundant functions. Nonetheless, Apol9a/b and the ApoL
family are ISGs that warrant further study in the context of homeostasis and during viral
infection.
We show that Apol9a expression can enhance activation of the ERK pathway and in turn
proliferation. The connection between the ERK pathway and proliferation is well supported by
previous studies, which show that ERK activation promotes cell cycle progression and cellular
differentiation (Rubinfeld and Seger, 2005; Shaul and Seger, 2007; Zhang and Liu, 2002).
Sustained ERK activation activates cyclin D1 expression and decreases CDK inhibitor levels to
allow cells to pass the G1 restriction point and enter the S phase of the cell cycle (Rubinfeld and
Seger, 2005). Thus, an increase in ERK activation would be able to increase the rate of cell
cycling.
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Modulation of the ERK pathway would allow for an additional level of control of
proliferation in epithelial organs beyond Wnt signaling, which is required for the maintenance of
stem and progenitor cells (Haegebarth and Clevers, 2009; Reya and Clevers, 2005). Wnt ligands
bind to their receptor complex and trigger the localization of b-catenin to the nucleus, where it
associates with transcription factors that activate multiple target genes to promote a baseline rate
of self-renewal and proliferation (Reya and Clevers, 2005). The source of Wnts is thought to be
local non-epithelial mesenchymal cells and, in the intestine, also Paneth cells (Farin et al., 2012).
In contrast, Type I IFN signaling can generate a signal at the systemic level. Downstream
activation of the ERK pathway could then increase the normal rate of cell cycling in stem and
progenitor cells. We propose that Type I IFNs provide additional control of epithelial
proliferation and healing under non-homeostatic conditions of infection and injury.
Finally, many human conditions are associated with elevated Type I IFN signatures,
similar to our observations in the Irgm1-/- mouse. For example, recombinant Type I IFN
treatment is used for a variety of disorders, including multiple sclerosis, hepatitis C, and some
malignancies (Ferrantini et al., 2007; Pawlotsky, 2014; Verweij and Vosslamber, 2013).
Morever, upregulation of Type I IFNs is associated with the Type I Interferonopathies, a group
of Mendelian disorders,(Crow, 2011; Rice et al., 2014a), as well as Systemic Lupus
Erythematosus (SLE) (Di Domizio and Cao, 2013; Kirou and Gkrouzman, 2013; Lichtman et al.,
2012). These diseases, which include Aicardi-Goutieres Syndrome (AGS) and
spondyloenchondrodysplasia (SPENCD) are proposed to arise from either i) inappropriate
activation of the Type I IFN response or ii) inadequate negative regulation of Type I IFN
production (Crow, 2011). While the molecular bases of some cases of Type I Interferonopathy
are known, many cases remain genetically uncharacterized. It would be interesting to determine
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whether there are gene changes in human IRGM in these cases that are linked with elevated Type
I IFN. In addition, we have only limited understanding of the role of Type I IFNs on disease
pathogenesis and progression. Our findings here suggest that elevated Type I IFNs may not be
sufficient to cause the severe autoimmunity seen in SLE, AGS, and SPENCD. We did not
observe the abnormal skin, brain, or bone dysplasias typically seen in these conditions in Irgm1deficient mice (results not shown). Instead, we observed increased epithelial turnover, with both
augmented cell proliferation and cell death. It is possible that this elevated turnover could
increase the risk for exposure of cell contents, such as nucleic acids, to the immune system.
Additional genetic or environmental contributions could then trigger autoimmunity to the
cellular components. Our findings show that constitutively elevated Type I IFNs can promote
systemic epithelial proliferation and cell death, thus expanding our knowledge of the host
response during infection and autoimmunity.
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Figure 3.1. MCMV infection promoted epithelial turnover in multiple organs.
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Figure 3.1. MCMV infection promoted epithelial turnover in multiple organs. A)
Representative immunohistochemistry for Ki67 in salivary gland (SG), exocrine pancreas,
kidney and liver of mock-infected mice or mice infected with 5x104 pfu MCMV (Smith strain),
d7 after intraperitoneal (i.p.) infection. Blue bars indicate 100µm, red bars measure 50µm. Black
boxes indicate insets (right-most column). Black arrowheads show examples of Ki67+ epithelial
cells that would be counted. B-C) Graph of the average number ± standard error of the mean
(SEM) of B) Ki67+ epithelial cells per high power field (hpf, 400X) and C) TUNEL+ bodies/hpf
relative to mock-infected animals. For B), approximately 25 hpf were quantified per organ and
only epithelial cells were counted, and for C), approximately 50 hpf per organ were quantified.
Graph of D) average crypt height and E) average number of mitotic figures ± SEM of 100 crypts
in mock- and MCMV-infected mice. Lengths of crypts were measured from histological slides
using ImageJ software. Mitotic figures were counted manually. For B) to E), mock-infected n=6
mice, MCMV-infected n=5 mice. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 by Student's t
test for each organ.
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Figure 3.2. Viral titers in MCMV- and MHV68-infected mice. A) Graph of average plaque
forming units (PFU)/mg of tissue ± standard deviation (SD) of kidney, liver, salivary gland and
small intestine of mock-infected and MCMV-infected mice 7 days after i.p. infection with 5x104
PFU MCMV (Smith strain). MCMV-infected n=5 mice, mock-infected n=6 mice. ND = not
detected. The limit of detection for this plaque assay was 40 PFU/organ. B) Graph of average
PFU/mg of tissue ± SD of kidney, liver, salivary gland and small intestine of mock-infected and
MCMV-infected mice 16 days after i.p. infection with 1x106 pfu MHV68. MHV68-infected n=4
mice, mock-infected n=4 mice. ND = not detected. The limit of detection for this plaque assay
was 100 PFU/organ.
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Figure 3.3. Different effects of MCMV, MHV68 and MNV on epithelial proliferation.
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Figure 3.3. Different effects of MCMV, MHV68 and MNV on epithelial proliferation.
A) Graph of the average number ± SEM of Ki68+cells/high power field (400X; hpf) relative to
mock infected animals in kidney, liver, SG and pancreas of mock-infected mice (n=3-4 mice)
and MHV68-infected mice (n=3-4mice) 16 days after i.p. infection with 1x106 pfu MHV68.
Approximately 25 hpf were counted per organ. *p<0.05; ***p<0.001 by Student's t test for each
organ. Graph of B) average crypt height and C) average number of mitotic figures ± SEM of 100
crypts of the small intestine in mock-infected (n=4 mice) and MHV68-infected mice (n=4 mice)
16 days after i.p. infection with 1x106 pfu MHV68. Averages are not significantly different by
Student's t test. Graph of D) average crypt height and E) average number of mitotic figures ±
SEM of 100 crypts of the small intestine in mock-infected (n=6 mice) and MNV-infected mice
(n=6 mice) 7 days after oral infection with persistent 3x107pfu MNV (CR6 strain). Averages are
not significantly different by Student's t test.
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Figure 3.4. Antiviral activity of serum from various mouse strains. Graph of antiviral activity
of serum from WT (n=12 mice), Irgm1-/- (n=16 mice), Ifnar-/- (n=4 mice), Irgm1-/-Ifnar-/- (n=5
mice), and Irgm1-/-IfnarVC (n=2 mice) mice. Blue bars indicate the addition of anti-Ifnar
antibody (Ab). Means ± SEM relative to untreated WT samples are shown. Means with
significant differences are indicated with different letters by uncorrected Fisher's LSD test.
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Figure 3.5. Elevated Type I IFNs in Irgm1-/- mice promoted enhanced epithelial turnover.
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Figure 3.5. Elevated Type I IFNs in Irgm1-/- mice promoted enhanced epithelial turnover.
A) Quantification of the average number of Ki67+cells/hpf ± SEM. n=6-11 mice per genotype.
B) Quantification of average number of TUNEL-positive cells per hpf ± SEM. n=5-10 mice per
genotype. For A) and B), approximately 50 hpfs were examined per organ. For each organ,
means with different letters are significantly different (p<0.05) by Tukey's multiple comparisons
test. C) Representative histology of small intestinal crypts of WT, Irgm1-/- and Irgm1-/-Ifnar-/mice. Red bar = 50µm. Yellow bars delineate the height of a crypt; red arrowheads mark mitotic
figures. Graph of D) average crypt height and E) average number of mitotic figures ± SEM of
100 crypts in WT, Irgm1-/-, and Irgm1-/-Ifnar-/- mice. Length of crypts was measured from
histological slides using ImageJ software. Mitotic figures were counted manually. WT n=23
mice, Irgm1-/- n=18 mice, Irgm1-/-Ifnar-/- n=18 mice from 4 independent experiments. F)
Quantification of the average number ± SEM of BrdU-positive cells per crypt. Mice were
injected with BrdU 1h before sacrifice. Immunofluorescent staining against BrdU was performed
on histological slides and the number of BrdU-positive cells was counted over an average
number of 50 crypts. WT n=3 mice, Irgm1-/- n=3 mice, Irgm1-/-Ifnar-/- n=2 mice. **p<0.01 by
Tukey's multiple comparisons test. G) Graph of the average migration rate ± SEM of small
intestinal epithelial cells in WT, Irgm1-/- and Irgm1-/- Ifnar-/- mice, calculated relative to WT for
100 villi/mouse using a 2-color thymidine analog experiment. WT n=11 mice, Irgm1-/- n=17
mice, Irgm1-/-Ifnar-/- n=9 mice from 4 independent experiments.
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Figure 3.6. Further evidence that elevated Type I IFNs in Irgm1-/- mice promoted enhanced
epithelial turnover.
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Figure 3.6. Further evidence that elevated Type I IFNs in Irgm1-/- mice promoted enhanced
epithelial turnover. A) Representative histology of Ki67 immunohistochemistry of kidney
tubules, liver hepatocytes, pancreatic acinar cells, and submandibular salivary mucinous and
serous glands of Irgm1-/- and WT mice. Red arrowheads indicate cells stained with Ki67. All
images taken at 200X magnification. B) Quantification of the average number of Ki67-positive
cells per high power field (400X) ± SEM in lung epithelium, thyroid gland epithelium, and
skeletal muscle cells. N=2-3 mice per genotype per organ. C) Graph of the average number ±
SEM of Ki67-positive cells per crypt base region (stem cell compartment), upper crypt region
(transit-amplifying compartment), or total crypt relative to WT. WT n=6 mice, Irgm1-/- n=6 mice,
Irgm1-/-Ifnar-/- n=2 mice. 20-50 crypts were counted per mouse. For each crypt region, different
letters indicate means with significant differences by Tukey's multiple comparisons test. D)
Representative immunofluorescent images of CldU and IdU stained small intestinal sections.
Red – CldU, Green – IdU, Blue – nuclei. CldU was injected 36h prior to sacrifice and IdU was
injected 24hrs prior to sacrifice. Yellow bar shows the distance cells have migrated in 12h.
Images taken at 200Xmagnification.
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Figure 3.7. Type I IFN-dependent enhanced turnover in Irgm1-/- mice was not due to
increased cell death. A) Graph of the average number ± SEM of TUNEL-positive bodies per
100 crypts. WT n=10 mice, Irgm1-/- n=12 mice, Irgm1-/- Ifnar-/- n=10 mice. B) Graph of the
average percentage ± SEM of non-viable intestinal crypt cells after 24h incubation with 0,
10UmL, and 50U/mL of recombinant murine IFNαA. WT, Ifnar1-/- and Irgm1-/- intestinal
epithelial cells were used. The percentages of non-viable cells were measured by Sytox 7'AAD
dead cell nucleic acid stain. P=0.3412 by ordinary ANOVA. N=2 replicates each group from 2
independent experiments. C) Graph of the fold change in mRNA expression of Mx2 and Oas2 in
WT and Irgm1-/- intestinal epithelial crypt cultures after addition of 2.5U/mL IFNα for 24h. The
expression of Mx2 and Oas2 relative to non-IFNα treated cells for each genotype is shown.
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Figure 3.8. Viral infection and Type I IFNs changed response to diclofenac-induced wound
healing.
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Figure 3.8. Viral infection and Type I IFNs changed response to diclofenac-induced wound
healing. A) Graph of the average number ± SEM of detectable ulcers per small intestine 18hr, 2
days (D2), and 4 days (D4) after i.p. injection of 60mg/kg dicloflenac sodium salt in sterile PBS.
N=3-8 mice per genotype per day. Results from 5 independent experiments. *p<0.05 by Tukey's
multiple comparisons test. B) Representative whole mount images of formalin-fixed small
intestinal wounds of WT, Irgm1-/- and Irgm1-/-Ifnar-/- mice 4 days after diclofenac injection.
Dotted black lines outline the wound. All images at 32X. C) Graph of the average distance
covered by WAE cells 4 days after colonic biopsy wounding. Quantification was performed
blinded on whole mount images of formalin-fixed wounds using Image J software. 10
measurements per wound were averaged. WT n=8 wounds in 4 mice, Irgm1-/- n=12 wounds in 4
mice, Irgm1-/-Ifnar-/-n=9 wounds in 3 mice. D) Representative whole mount images at 90X
magnification of colonic biopsy wounds 4 days after wounding. Black arrows delineate the
distance migrated by WAE cells. E) Graph of the average number ± SEM of detectable ulcers
per small intestine 18hr, and 4 days (D4) after i.p. injection of 60mg/kg dicloflenac sodium salt
in sterile PBS. Diclofenac was administered 4 days after mock infection or infection with 5x104
PFU MCMV (Smith strain). Mock 18hr n=6 mice, D4 n=4 mice; MCMV-infected 18hr n=7
mice, D4 n=4 mice. *p<0.05 by Tukey's multiple comparisons test. F) Representative whole
mount images at 32X magnification of small intestinal wounds 18hr after diclofenac injection in
mock- and MCMV-infected mice. Dotted black lines outline the wound.
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Figure 3.9. Irgm1-/- mice had enhanced wound healing dependent on Type I IFN signaling.
Representative whole mount images of formalin-fixed small intestinal wounds of WT, Irgm1-/and Irgm1-/-Ifnar-/- mice 18h, 2d and 4d after injection of 60mg/kg diclofenac sodium salt in
sterile PBS. Images are shown for 1 mouse each genotype each day at 32X magnification. Dotted
black lines outline the wounds.
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Figure 3.10. Type I IFNs signaled through macrophages to indirectly promote epithelial
turnover.
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Figure 3.10. Type I IFNs signaled through macrophages to indirectly promote epithelial
turnover. A-B) Graph of A) the average crypt height and B) the average number of mitotic
figures of 100 crypts ± SEM in control (n=9 mice), Irgm1-/- (n=8 mice), Irgm1-/-IfnarVC (n=7
mice), and IfnarVC (n=6 mice) mice. Control mice were Irgm1+/+Ifnarf/f-VillinCre negative.
Means with different letters are significantly different by Tukey's multiple comparisons test. C)
Graph of the average crypt height and average number of mitotic figures (MF)/100 crypts ± SEM
in WT and Ifnar-/- mice injected i.p. with saline or 5mg/kg polyI:C for 4 days. WT n=13 mice for
each treatment; Ifnar-/- n=5 mice for each treatment. D) Graph of the average crypt height and
average number of MF/100 crypts ± SEM in control and IfnarLysM mice injected i.p. 5mg/kg
polyI:C for 4 days. Control: saline n=9 mice, polyI:C n=11 mice. IfnarLysM: saline n=7 mice,
polyI:C n=8 mice. Control mice were Ifnarf/f-LysMCre negative. Results compiled from 3
independent experiments. E) Graph of the average crypt height and average number of
MF/100crypts ± SEM in WT mice treated with isotype control (saline n=5 mice, polyI:C n=6
mice) or anti-Ly6G (saline n=6 mice, polyI:C n=6 mice). Results compiled from 2 independent
experiments. For C) to E), the averages ± SEM relative to saline-treated mice are shown.
*p<0.05; **p<0.01; ****p<0.0001 by Student's t test.
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Figure 3.11. IFNα did not directly increase proliferation of epithelial cells in vitro. A)
Quantification of the average percentage ± SEM of S phase cells after 24h incubation with 0,
10UmL, and 50U/mL of recombinant murine IFNαA. WT, Ifnar1-/- and Irgm1-/- intestinal
epithelial cells were used. Percent S-phase cells were measured by EdU incorporation assay.
P=0.7813 by ordinary ANOVA. N=2 replicates each group from 2 independent experiments.
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Figure 3.12. PolyI:C injection induced Type I IFNs and promoted epithelial proliferation in
WT and IfnarVC mice.
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Figure 3.12. PolyI:C injection induces Type I IFNs and promote epithelial proliferation in
WT and IfnarVC mice. A) Graph of average MFI ± SD as a measure of anti-viral activity in
serum of polyI:C-injected or saline-injected WT mice over time. N=3 mice each group. Mice
were injected daily with 5mg/kg polyI:C or saline and serum samples taken at 0, 3 and 9 days.
Serum was assayed for the ability to inhibit VSV-GFP infection in L929 cells in the bioassay
system. B) Representative histology of WT mice injected with saline or 5mg/kg polyI:C daily for
4 consecutive days and sacrificed on day 5. Yellow bars delineate the height of a crypt; red bars
=100µm. C-D) Quantification of C) the average crypt height ± SEM and D) the average number
of mitotic figures/100crypts ± SEM in saline-injected and polyI:C-treated IfnarVC mice. Saline
n=2 mice, polyI:C n=3 mice. *p<0.05 by Student's t test.
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Figure 3.13. Control information for IfnarLysM and neutrophil depletion experiments. AB) Graphs of antiviral activity present in serum of A) Control and IfnarLysM mice (saline n=4
mice, polyI:C n=5 mice for each genotype) and B) neutrophil-depleted mice (isotype control (IC)
n=1 mouse each treatment, neutrophil-depleted n=2 mice each treatment). 500ug/mouse of antiLy6G antibody or rat IgG2 IC was give i.p. to mice on days -1 and 3 during 4 days of i.p.
polyI:C administration to WT mice. *p<0.05; **p<0.01; ****p<0.0001 by Sidak's multiple
comparisons test. C) Graph of the percentage of blood neutrophils after administration of
depleting antibody. The percent of white blood cells that were neutrophils in whole blood were
counted manually by blood smear. Representative experiment out of 2 independent experiments
shown.
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Figure 3.14. Levels of multiple growth factors were unchanged between mice with elevated
Type I IFNs and controls. A-B) Graph of the serum levels of multiple known growth factors
measured by ELISA in A) saline-treated (4 pools of 2-3 mice, 10 mice total) and polyI:C-treated
WT mice (4 pools of 2-3 mice, 9 mice total), and B)WT (6 pools of 1-5 mice, 13 mice total) and
Irgm1-/- mice (6 pools of 1-6 mice, 14 mice total).
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Figure 3.15. Microarray analysis revealed Apol9a/b upregulation in Irgm1-/- macrophages
and tissues. A) Heat map of genes that significantly differed in expression in salivary gland,
small intestine, and isolated macrophages between Irgm1-/- mice and WT mice, with p<0.05 by
ANOVA (463 genes), displayed after hierarchical clustering. Whole genome microarray
analysis was performed on samples from 3 to 4 mice per genotype per tissue. Rows represent
mice and columns represent genes. Black arrows indicate the location of Apol9a and Apol9b. B)
Graph of the fold change in Apol9a and Apol9b gene expression in Irgm1-/- mice relative to WT
mice in the three microarrays.
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Gene
Name

Fold
change
(Salivary
gland)

Fold
change
(Small
intestine)

8.14

3.77

40.13

1.98

20.79

2.18

Membrane

0.71

0.96

0.0061

Cell membrane

0.60

0.87

2.12

0.0014

Cell membrane

0.80

1.59

2.10

0.0085

Membrane

0.67

0.98

Protein name

Fold change
(Macrophages)

P
value

Rtp4

Receptor transporting
protein 4

3.02

0.0098

Apol9b

Apolipoprotein L 9b

2.95

0.0057

Apol9a

Apolipoprotein L 9a

2.92

0.0056

Slc12a2

Solute carrier family
12 member 2

2.76

0.0032

Cldn14

Claudin 14

2.25

Cldn2

Claudin 2

Slc12a8

Solute carrier family
12 member 8

Cellular
component
(Gene
Ontology)
Membrane
Extracellular
region
Extracellular
region

Table 3.1. Membrane-associated and secreted factors upregulated in Irgm1-/- colonic
macrophages and tissues. Table of genes upregulated >2-fold with p-value <0.01 by ANOVA
in whole genome microarray analysis of Irgm1-/- colonic macrophages compared to WT (3 to 4
mice per genotype per tissue). Cellular component was determined by Gene Ontology (GO)
analysis. The fold change in salivary gland and distal small intestine is shown for each factor.
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Figure 3.16. The interferon-stimulated genes Apolipoprotein L9a and b were elevated in
stromal and epithelial cells of Irgm1-/- and MCMV-infected mice.
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Figure 3.16. The interferon-stimulated genes Apolipoprotein L9a and b were elevated in
stromal and epithelial cells of Irgm1-/- and MCMV-infected mice. A) Quantification of the
average expression ± SEM of Apol9a/b mRNA in Irgm1-/- small intestine, salivary gland and
isolated colonic macrophages relative to WT tissue as measured by qRT-PCR. N=3 mice per
genotype. Primers were designed to amplify both Apol9a and b. *p<0.05 by Student's t test for
each organ. B) Quantification of the average expression ± SEM of Apol9a/b mRNA in MCMVinfected salivary gland, liver and kidney relative to mock-infected tissue as measured by qRTPCR. Mock-infected n=3 mice, MCMV-infected n=5 mice. ***p<0.001 by Student's t test for
each organ. C) Representative in situ hybridization images for Apol9a in WT and Irgm1-/salivary gland. Apol9a expression is indicated by dark purple staining. Lower images are insets
(area within the black box) of upper images. Blue bar indicates 200µm, red bar indicates 100µm.
Black arrowhead indicates an Apol9a-positive stromal cell. Dashed black lines outline an
Apol9a-positive epithelial gland. D) Representative Apol9a in situ hybridization images of WT
and Irgm1-/- small intestine. Black box indicates area of inset (lower images). Black box in
Irgm1-/- section shows a focus of Apol9a expression. Blue bars indicate 200µm; red bars indicate
100µm.
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Figure 3.17. Apol9a was stimulated by Type I IFNs, can be secreted, and can be indirectly
stimulated. A) Graph of Apol9a/b mRNA expression in WT and Ifnar-/- bone marrow-derived
macrophages stimulated with 0U/mL, 1U/mL, and 10U/mL of recombinant murine IFNαA for
8h. WT n=1, Ifnar-/- n=1. 2^-dCt values were calculated relative to GAPDH expression. Primers
were constructed to amplify both Apol9a and Apol9b. B) Anti-Flag immunoblot of cell lysates
and supernatant of 293FT cells overexpressing Apol9a-Flag. Supernatant was concentrated 5X
after harvesting. 2 separate replicates shown, along with untransfected 293FT cells. C)
Representative images of in situ hybridization of Apol9a in Irgm1-/- VC- and Irgm1-/- VC+ small
intestine. Apol9a expression is indicated by dark purple staining. Length of blue bar indicates
100µm.
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Figure 3.18. Apol9a expression correlated with Ki67 expression in salivary gland.
Representative serial sections of Apol9a in situ hybridization and Ki67 immunohistochemistry
(IHC) of WT and Irgm1-/- salivary gland. Red bar indicates 200µm.
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Figure 3.19. Apol9a augmented epithelial proliferation through ERK1/2 activation.
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Figure 3.19. Apol9a augmented epithelial proliferation through ERK1/2 activation. A)
Schematic representation of Cdc25A-CBRLuc fusion protein expressed in the endogenous
Cdc25A locus. B) Gray scale photograph and bioluminescence image of gastrointestinal tract of
wild-type mice (A/A) and knock-in mice that were heterozygous (A/Luc) for the Cdc25ACBRLuc fusion protein. Mice were injected intraperitoneally with D-luciferin, sacrificed and the
indicated organs were isolated and subjected to bioluminescence imaging ex vivo. Photon flux is
indicated by the pseudocolored heatmap. C) Bioluminescence image of Cdc25A-CBRLucexpressing colonic epithelial cell growth over time. Colonic crypts were isolated from knock-in
mice that were homozygous (ALuc/ALuc) for the Cdc25A-CBRLuc fusion protein and colonic
epithelial spheroid cultures were established. 16h later, fresh media containing D-luciferin was
added (t = 0h) and bioluminescence was measured 0h, 7.5h, 12h, and 24h later. Fresh media with
D-luciferin was replaced at 24 h post imaging and bioluminescence was measured 32h and 48h
later. D) Graph shows the average fold change in bioluminescence (photon flux) relative to 0h
after addition of D-luciferin substrate. n = 6 wells from two independent experiments were
measured and data are presented as mean ± SEM. *p<0.05, **p<0.01. ****p<0.001 as measured
by Dunnett’s multiple comparison test. E) Plot of the average absorbance at 490nm obtained by
MTS assay of Cdc25A-CBRLuc expressing colonic epithelial spheroid cultures at 0h and 48h of
growth. Absorbance was corrected by subtracting background absorbance (media only).
Triplicate samples were measured and data are presented as mean ± SEM. Asterisks indicate
****p<0.001 as measured by Student's t test. F-G) Graph of the fold change in luminescence
during a 24h period after addition of D-luciferin in Cdc25A-CBRLuc intestinal spheroid cultures
cultured with F) media containing Rspo3 and Wnt3a or G) Wnt3a only. Cells express Rspo3,
Apol9a, or a negative control. The average fold change in luminescence relative to luminescence
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measured at 4h, ± SEM, of 3 independent experiments is shown, with 12-18 replicates per cell
line per experiment. F) p=0.0389 by repeated measures 2-way ANOVA. G) p= 0.0574 by
repeated measures 2-way ANOVA. Asterisks indicate **p<0.01 and ****p<0.0001at 24h only
by Dunnett's multiple comparisons test with comparison to control cells. H) Western blot of
phosphorylated and total ERK1/2 (p42 and p44) of cells expressing a negative control, Rspo3, or
Apol9a. Background-subtracted representative image from 3 independent experiments is shown.
I) Graph of the fold change in luminescence measured during a 24h period after addition of Dluciferin and differing concentrations of MEK inhibitor U0126 in Apol9a-expressing Cdc25ACBRLuc intestinal spheroid cultures. The average fold change in luminescence relative to
luminescence measured at 4h, ± SEM, of 2 independent experiments is shown, with 3 replicates
per dose per experiment. P=0.0066 by repeated measures 2-way ANOVA.
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Figure 3.20. Apol9a did not increase epithelial proliferation by enhancing Wnt activation.
A) Gel image of PCR products from Apol9a PCR amplification (30 cycles) from cDNAs
generated from small intestinal epithelial cells expressing a control construct or Apol9a and gel
image of PCR products from Rspo3 PCR amplification (40 cycles) from cDNAs from small
intestinal epithelial cell cultures expressing either a control construct or Rspo3. B) Quantification
of the number of β-catenin-positive nuclei per 100 crypts in WT (n=5 mice) and Irgm1-/- (n=5
mice) small intestinal tissue after immunohistochemistry staining for β-catenin. C)
Representative images of Axin2 localization by in situ hybridization in WT and Irgm1-/- small
intestinal sections. D) Quantification of the percentage of S phase cells of small intestinal
epithelial cells expressing Apol9a, Rspo3, and control after plating in Rspo3+Wnt3a media or
Wnt3a only media for 24h. EdU was then added for 2h, and the percentage of EdU positive cells
(S-phase cells) was measured by flow cytometry.
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Figure 3.21. Apol9a was associated with activated ERK, and inhibition of ERK activation
decreased epithelial proliferation. A) Background-subtracted image of phospho-kinase dot blot
array of cell lysates from control, Rspo3, and Apol9a-expressing intestinal epithelial cells. In this
commercially available kit, antibodies against phosphorylated kinase targets were dotted onto the
array membrane in duplicate before incubation with cell lysates. Red boxes outline dot blot
corresponding to phosphorylated ERK1/2, while blue boxes outline reference spots. B)
Background-subtracted image of immunoblot detecting phosphorylated ERK1/2 (P-ERK) and
total ERK from cell lysates of control small intestinal epithelial cells incubated with increasing
concentration of MEK inhibitor U0126 for 24h immediately after passage. C) Graph of the fold
change in luminescence measured during a 24h period after addition of D-luciferin and differing
concentrations of MEK inhibitor U0126 in control Cdc25A-FLuc intestinal spheroid cultures.
The average fold change in luminescence relative to luminescence measured at 4h, ± SEM, of 2
independent experiments is shown, with 3 replicates per dose per experiment. P=0.0006 by
repeated measures 2-way ANOVA.
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Figure 3.22. Macrophages promoted epithelial proliferation in trans via Apol9a expression.
Graph of the fold change in luminescence measured during a 28h period after addition of Dluciferin of Cdc25A-CBRLuc intestinal spheroid cultures cultured with WT macrophages
expressing Apol9a or a control construct, or without macrophages. The average fold change in
luminescence relative to luminescence measured at 4h, ± SEM, of 3 ind. expts. is shown, with 45 technical replicates per experiment. P=0.0297 by repeated measures 2-way ANOVA. *p<0.05,
***p<0.001 at 24hrs only by Sidak's multiple comparisons test.
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CHAPTER 4:
Summary and Future Directions
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SUMMARY
These studies demonstrated that the immune response to viral infection can have broad
effects on host physiology. These findings are schematized in Figure 4.1. Specifically, we
showed that infection with chronic, systemic herpesviruses increased epithelial turnover in
multiple organs. Infection with a local RNA virus, MNV, did not increase epithelial turnover in
the intestine where it is tropic. I hypothesized that this effect was due to the innate anti-viral
cytokines Type I IFNs. However, studying Type I IFN responses in a viral infection model is
difficult, as loss of these cytokines can result in uncontrolled viral replication, morbidity, and
mortality. To this end, I employed a mouse model with persistently elevated Type I IFNs even in
the absence of exogenous viral infection, the Irgm1-/- mouse.
I found that Irgm1-/- mice had elevated Type I IFNs in the lung and serum, starting as
early as 7 days after birth and up to at least 17 weeks of age. IFNα in particular was increased in
the serum of Irgm1-/- mice. A complete loss of Irgm1 was required to promote Type I IFN
production, as Irgm1+/- mice had levels of IFNs similar to WT controls. I verified that the Type I
IFNs were functional, since they induced ISG expression in multiple organs. Irgm1-/- mice were
protected against influenza A infection, likely due to a primed antiviral response. Investigation of
lung histology revealed the presence of aggregates of mixed immune cells (T and B cells,
dendritic cells, macrophages) in Irgm1-/- mice even without influenza infection. The formation of
these aggregates was dependent on Type I IFN signaling. These aggregates may have played a
role in antiviral defense against flu infection in Irgm1-deficient animals.
I next attempted to determine the source of increased Type I IFN production in Irgm1-/mice. IFNα and IFNβ1 transcripts were unchanged in multiple organ homogenates of Irgm1-/and WT mice. Irgm1-deficient bone marrow-derived dendritic cells and intestinal epithelial cells
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had similar sensitivity to polyI:C stimulation compared to WT cells. Bone marrow cells from
Irgm1-/- and WT mice had comparable surface expression of the Type I IFN receptor Ifnar. I
found that T and B cells and thus the adaptive immune system were not required for enhanced
production of Type I IFNs in Irgm1-deficient animals, but that liver macrophages played a role
in this process. Finally, I established that broad-spectrum antibiotic treatment did not diminish
increased Type I IFN levels in Irgm1-/- mice. Together, these results revealed a previously
unreported role for Irgm1 in macrophages in the negative regulation of Type I IFN production.
The Irgm1-/- mouse also enabled the exploration of the impact of Type I IFNs on host
physiology. Similar to what I observed in herpesvirus infection, Irgm1-/- mice also had increased
epithelial turnover in multiple organs. Using Irgm1-/-Ifnar-/- mice, I verified that this effect was
dependent on Type I IFN signaling. Accelerated turnover was not universal, as there was no
increased proliferation in lung epithelium, thyroid epithelium, or skeletal muscle. Increased
proliferation, not cell death, seemed to be the primary driver of increased turnover. Notably,
Type I IFNs promoted enhanced healing in two different models of wound repair in Irgm1-/mice. I discovered that Type I IFNs did not act directly on the epithelial cells to promote
turnover. Instead, Type I IFN signaling through macrophages was important for this process. I
used a microarray screening approach to determine novel candidates that could promote
epithelial proliferation. I found that the ISGs Apolipoprotein L9a and b were elevated in Irgm1-/mice and also virally-infected animals. Finally, expression of Apol9a in intestinal epithelial cells
could increase proliferation through enhanced ERK activation. These findings demonstrate a
novel role for Type I IFNs in modulating epithelial turnover through the function of previously
uncharacterized ISGs (Figure 4.1).
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FUTURE DIRECTIONS
Determine the mechanism by which Irgm1 negatively regulates Type I IFN production
Chapter 2 describes the elevation of Type I IFNs in Irgm1-/- mice, but what causes this
increase is unclear. Based on our preliminary results and prior reports in the literature, I
hypothesize that Irgm1 functions to regulate sensing of intracellular nucleic acid debris in tissue
macrophages.
Our preliminary evidence suggested that hepatic macrophages play a role in the
production of Type I IFNs in Irgm1-/- mice. To support our findings using clodronate liposomes
to deplete liver macrophages, we are currently generating an Irgm1flox/flox mouse. This line can
then be crossed to a LysM-Cre line to knock out Irgm1 in macrophages and granulocytes only. If
Irgm1 acts in macrophages to negatively regulate Type I IFN production, these Irgm1flox/flox
LysM-Cre animals should still have elevations in systemic Type I IFNs. If instead Irgm1 acts
through an alternative or additional cell type, Type I IFN levels should be similar to controls. In
this latter case, the Irgm1flox/flox mouse can be crossed to different Cre lines to find the relevant
cell type.
To verify that Irgm1-deficient Kupffer cells produce increased Type I IFNs, we could
isolate liver macrophages from WT and Irgm1-/- mice and assess mRNA expression and protein
production of Type I IFNs. I predict that Type I IFN expression would be enhanced in Irgm1-/liver macrophages, either at baseline and/or upon addition of polyI:C or other stimuli. We could
also assess the localization of Type I IFN production in vivo using in situ hybridization for IFNα
and anti-IFNα antibodies. Co-localization with liver macrophages would demonstrate that these
cells are the source of Type I IFNs.
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The next step would be to determine a molecular mechanism for enhanced Type I IFN
production in liver macrophages. First, the location of Irgm1 within the cell should be
determined. Previous studies have shown Irgm1 localization onto the Golgi membrane as well as
late endosomal and lysosomal compartments in IFNγ-treated cells (Martens et al., 2004; Zhao et
al., 2010). These studies were conducted in L929 fibroblasts, TIB-75 hepatocytes, RAW264.7
macrophages, and murine embryonic fibroblasts (MEFs). It would be informative to see if Irgm1
also localizes in a similar manner in primary Kupffer cells, and if it co-localizes with membranebound IFN regulators such as STING and MAVS. Binding of Irgm1 to these proteins or
associated protein complexes could be determined by co-immunoprecipitation. Such colocalization would suggest that Irgm1 could regulate the production of Type I IFNs through these
adaptors of nucleic acid-sensing pathways. Kupffer cells in particular would have a high burden
of intracellular nucleic acids due to their function in clearing erythrocyte nuclei, apoptotic
bodies, and other debris.
It is also possible that Irgm1 functions by a completely different, unknown mechanism.
In this case, it would be informative to determine novel protein interactions by coimmunoprecipitation and mass spectroscopy. Whole genome microarray or RNA-seq analysis of
the Type I IFN-producing cell in Irgm1-/-and WT mice could also be performed.

Clarify viral contributions to increased epithelial turnover
An additional point of interest is that some but not all viruses can induce increased
epithelial turnover. We found that MCMV and MHV68, two DNA herpesviruses, could increase
epithelial turnover, whereas MNV, an RNA virus, could not. One explanation could be that
different viruses induce or inhibit varying levels of Type I IFNs. Viruses that induce higher
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levels of interferons may be able to promote greater levels of epithelial proliferation. To test this,
we could measure Type I IFN levels at multiple time points after infection with MCMV, MHV68
and MNV. Additional viral types could be tested to further elucidate whether certain classes of
viruses stimulate epithelial turnover. It may be that a systemic viral infection is required to
promote epithelial proliferation (as observed in MCMV and MHV68 infection), compared to an
isolated infection (seen in MNV infection). A further advantage of using these murine viruses is
that viral mutants can be generated to test whether certain viral components are required to
produce a response.
In addition, we only examined epithelial turnover at one time point for each virus, day 7
after infection for MNV and MCMV, and day 16 for MHV68. These time points were chosen as
they were the time when these viruses are establishing persistent chronic infection (Munks et al.,
2006; Nice et al., 2013; Tibbetts et al., 2003). However, it would also be important to look at
epithelial turnover at other times, including the earlier acute phase and later during chronic
infection.

Distinguish differences in epithelial organs that result in discrepant proliferative responses to
Type I IFNs
One notable finding was that not all epithelial organs had proliferative responses to Type
I IFN stimulation. Increased turnover was observed in small intestine, kidney, salivary gland,
liver, and pancreatic epithelia, but not lung or thyroid epithelia, nor skeletal muscle of Irgm1-/mice. It would be interesting to extend these findings to other organs, including epithelial organs
such as skin, esophagus, uterus, and bladder, as well as non-epithelial organs including cardiac
muscle, smooth muscle, neuronal tissue, and adipose tissue. Intriguingly, a glandular
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organization is shared among those epithelial organs examined so far that had increased turnover
in Irgm1-/- mice. By investigating additional tissues, patterns may be distinguished that could aid
in our understanding of this phenomenon.
We found that, at least in the case of the small intestine, Type I IFNs signaled indirectly
through macrophages to promote increased epithelial turnover. It could be that there are
differences in the tissue macrophage populations that reside in the disparate organs, resulting in
some that promote turnover in response to Type I IFNs, and some that do not. The macrophages
in these tissues could be isolated and compared by flow cytometry and/or microarray analysis to
identify these differences. The tissue localization of the macrophages could also play a role in
determining epithelial responses. In the tissue types that had increased epithelial proliferation,
macrophages are situated between and around the glandular epithelium. This close proximity
may enable the macrophages to influence the surrounding epithelial cells. In vitro primary
macrophage-epithelial co-culture experiments would be valuable in dissecting out these
interactions.

Characterize the function of Apolipoprotein L9a/b
Finally, this project demonstrates that Apolipoprotein L9a and b, highly homologous
interferon-stimulated genes, are involved in Type I IFN-induced epithelial turnover by enhancing
ERK activation. However, many questions remain regarding the localization, function, and
protein interactions of these proteins.
We are currently generating an Apol9a/b knockout mouse using the CRISPR/Cas9
system. Once obtained, this knockout will allow in depth loss-of-function studies into the role of
Apol9a/b in viral infection, epithelial turnover, and potentially undiscovered physiological
138	
  
	
  

processes. Initial characterization of the knockout, if it is not embryonic lethal, should consist of
a careful gross and histological examination of conventionally raised animals without additional
challenge. The Apol9a/b knockout mouse could be administered polyI:C injections and/or
crossed with the Irgm1-/- mouse line to determine whether Apol9a/b is absolutely necessary for
increased epithelial proliferation in response to Type I IFNs. One previous study suggested a role
for Apol9b in anti-viral protection in neurons (Kreit et al., 2014). It would thus be informative to
infect Apol9a/b knockout mice with different viruses and examine not only the epithelial
proliferative response, but also the antiviral immune response.
In the shorter term, Apol9a/b knockdown primary epithelial cell lines could be created.
This would allow for examination of epithelial responses in vitro. For example, preliminary
evidence suggests that co-culture of bone marrow-derived macrophages with intestinal epithelial
cells enhances epithelial proliferation (Figure 4.2). Knocking down Apol9a/b in the epithelial
cells would uncover whether these ISGs are necessary for epithelial proliferation under
stimulative conditions. It would also be interesting to determine whether Apol9a/b expression
under baseline conditions is also necessary for epithelial proliferation.
An additional question is where Apol9a/b is localized within the cell and whether it is
secreted. Our preliminary evidence suggests that Apol9a can be secreted from 293FT cells.
However, whether this is true in a macrophage cell line or primary macrophages and epithelial
cells is unclear. To this end, a Flag-tagged Apol9a construct could be expressed within these cell
types. Immunofluorescence against the Flag-tag could localize Apol9a within the cell.
Alternatively, cell fractionation and immunoblotting against various cellular compartments could
be performed. Cells could be cultured and supernatant immunoblotted for secreted Apol9a. In
addition, it may be prudent to generate a few antibodies against Apol9a and b, which are
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currently not commercially available. This would prevent mislocalization or inhibition of
function due to the Flag-tag.
Whether or not Apol9a/b is secreted, co-immunoprecipitation and mass spectroscopy
could be used to identify its binding partner(s). It would be interesting to determine whether
Apol9a/b interacts directly with ERK or if there are adaptors or intermediate signaling proteins
that are involved. Findings regarding Apol9a/b could extend further to other members of the
Apolipoprotein L family, of which little is currently known.
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Figure 4.1. Model of Type I IFN induction of increased epithelial turnover. Type I IFNs are
elevated in both viral infection and in mice lacking Irgm1. These cytokines signal through
macrophages, stimulating expression of Apol9a/b and promoting Apol9a/b expression in
epithelial cells themselves. Epithelial cell proliferation and cell death is increased, resulting in
enhanced wound healing.
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Figure 4.2. Co-culture with macrophages increased proliferation of epithelial cells. Graph of
average luminescence of Cdc25A-CBRLuc small intestinal epithelial spheroid cells as measured
by blank-subtracted relative light units (RLU). Spheroid cells were trypsinized and plated in 96well plates either with bone marrow-derived macrophages (BMM) (n=2 sets of BMM from 2
mice, 4 technical replicates) or without co-culture (4 technical replicates). All cells were plated
in Matrigel and covered with 100µL of 50% L-WRN conditioned media and ROCK inhibitor.
Luminescence was measured at 4, 8, 12, 24 and 33 hours after plating using a plate reader.
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